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1. INTRODUCTION 
During past few decades, significant advance have been made in the area of 
controlled release as evidenced by an increasing number of patents, publication, as 
well as commercial controlled release products for the delivery of variety of 
pharmaceutical compounds1. With a controlled release formulation, predictable and 
reproducible release rate can be achieved, at the target site for desired duration2. 
This results in optimum biological response, prolonged efficacy, decreased toxicity 
as   well as reduction in required dose levels as compared to the conventional mode 
of   delivery. Hydrophilic polymer matrix is widely used for formulating a controlled 
release dosage forms.3, 4 
 
Fig 1: Diagram of controlled release verses sustained release 
Oral route still remains the most popular for drug administration by virtue of its 
convenience to the patient. A sizable portion of orally administered dosage forms so 
called conventional, are designed to achieve maximal drug bioavailability by 
maximizing the rate and extent of absorption. While such dosage forms have been 
useful, frequent daily administration is necessary, particularly when the drug has a 
short biological half life. This may result in wide fluctuation in peak and trough 
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steady-state drug levels, which is undesirable for drugs with marginal therapeutic 
indices. Moreover, patient compliance is likely to be poor when patients need to take 
their medication three to four times daily on chronic basis. Fortunately, these 
shortcomings have been circumvented with the introduction of controlled release 
dosage forms. These dosage forms are capable of controlling the rate of drug 
delivery, leading to more    Controlled drug levels and hence therapeutic action as 
outlined. 
 
 
 
 
 
Fig.2: Schematic drawing of plasma concentration-versus-time profiles following 
administration of three immediate-release dosage forms versus one single 
controlled-release dosage form. 
Terminology 
Modified release delivery system may be divided conveniently in to four 
categories.6 
A. Delayed Release 
These system are those that used repetitive intermittent dosing of a drug from 
one or more immediate release units incorporated in to a single dosage form. 
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Examples of delayed release system include repeat action tablets and capsules and 
enteric coated tablets were timed release is achieved by a barrier coating. 
B. Sustained Release 
These system include any drug delivery system that achieves slow release of 
drug over an extended period of time. 
 I. Controlled release 
These system also provide slow release of time over a extended period of 
time and also can provide some control weather this be of a temporal special nature 
or both, of drug release in the body, or in other words, the system is successful at 
maintain constant drug levels in the target tissue or cells.  
II. Extended release 
Pharmaceutical dosage forms that release the drug slower than the normal 
manner at predetermined rate and necessarily reduce the dosage frequency by two 
folds. 
C. Site specific targeting 
These systems refer targeting of a drug directly to a certain biological 
location in these cases the target is adjacent to or in the diseased organ or tissue. 
D. Receptor targeting 
This system refers to targeting directly to certain biological location. In these 
case the target is particular receptor for a drug with in a organ or tissue. Site specific 
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targeting and receptor targeting system satisfy the special aspects of the drug 
delivery and also considered to be controlled drug delivery system. 
1.1.1. ADVANTAGES OF MATRIX TABLET7, 8 
 Easy to manufacture  
 Versatile, effective and low cost 
 Can be made to release high molecular weight compounds 
 The sustained release formulations may maintain therapeutic concentrations 
over prolonged periods. 
 The use of sustain release formulations avoids the high blood concentration.  
1.1.2. DISADVANTAGES OF MATRIX TABLET7, 8 
 The remaining matrix must be removed after the drug has been released.  
 High cost of preparation. 
 The release rates are affected by various factors such as, food and the rate 
transit through the gut. 
 The drug release rates vary with the square root of time. Release rate 
continuously diminishes due to an increase in diffusion resistance and/or a 
decrease in effective area at the diffusion front.  
 However, a substantial sustained effect can be produced through the use of 
very slow release rates, which in many applications are indistinguishable from 
zero-order.  
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1.1.3. PHYSICOCHEMICAL FACTORS INFLUENCING RELEASE FROM 
MATRIX TABLET 
Dose size9:  
For orally administered systems, there is an upper limit to the bulk size of the 
dose to be administered. In general, a single dose of 0.5-1.0g is considered maximal 
for a conventional dosage form. This also holds for sustained release dosage form. 
Margin of safety involved in administration of large amount of a drug with a narrow 
therapeutic range.  
Ionization, pka and aqueous solubility10: 
Most drugs are weak acids or bases. Since the unchanged form of a drug 
preferentially permeates across lipid membranes, it is important to note the 
relationship between the pka of the compound and the absorptive environment. 
Presenting the drug in an unchanged form is advantageous for drug permeation. 
Unfortunately, the situation is made more complex by the fact that the drug’s 
aqueous solubility will generally be decreased by conversion to unchanged form. 
Delivery systems that are dependent on diffusion or dissolution will likewise be 
dependent on the solubility of the drug in aqueous media. These dosage forms must 
function in an environment of changing pH, the stomach being acidic and the small 
intestine more neutral, the effect of Ph on the release process must be defined. 
Compounds with very low solubility (<0.01mg/ml) are inherently sustained, since 
their release over the time course of a dosage form in the GI tract will be limited by 
dissolution of the drug. So it is obvious that the solubility of the compound will be 
poor choices for slightly soluble drugs, since the driving force for diffusion, which is  
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the drug’s concentration in solution, will be low. 
Partition Coefficient11: 
When a drug is administered to the GI tract, it must cross a variety of 
biological membranes to produce a therapeutic effect in another area of the body. It 
is common to consider that these membranes are lipid; therefore the partition 
coefficient of oil-soluble drugs becomes important in determining the effectiveness 
of membrane barrier penetration. Compounds which are lipophilic in nature having 
high partition coefficient are poorly aqueous soluble and it retain in the lipophilic 
tissue for the longer time. In case of compounds with very low partition coefficient, 
it is very difficult for them to penetrate the membrane, resulting in poor 
bioavailability. Furthermore, partitioning effects apply equally to diffusion through 
polymer membranes. The choice of diffusion-limiting membranes must largely 
depend on the partitioning characteristics of the drug.  
Stability:  
Orally administered drugs can be subject to both acid-base hydrolysis and 
enzymatic degradation. Degradation will proceed at a reduced rate for drugs in solid 
state; therefore, this is the preferred composition of delivery for problem cases. For 
the dosage form that are unstable in stomach, systems that prolong delivery over 
entire course of transit in the GI tract are beneficial; this is also true for systems that 
delay release until the dosage form reaches the small intestine. Compounds that are 
unstable in small intestine may demonstrate decreased bioavailability when 
administered from a sustaining dosage form. This is because more drugs is delivered 
in the small intestine and, hence, is subject to degradation. 
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1.1.4. BIOLOGICAL FACTORS INFLUENCING RELEASE FROM 
MATRIX TABLET 
Biological half-life: 12 
The usual goal of an oral SR product is to maintain therapeutic blood levels 
over an extended period of time. To achieve this, drug must enter the circulation at 
approximately the same rate at which it is eliminated. The elimination rate is 
quantitatively described by the half-life. Each drug has its own characteristic 
elimination rate, which is the sum of all elimination processes, including 
metabolism, urinary excretion and all over processes that permanently remove drug 
from the blood stream.  
Absorption:  
Since the purpose of forming a SR product is to place control on the delivery 
system, it is necessary that the rate of release is much slower than the rate of 
absorption. If we assume that the transit time of most drugs in the absorptive areas 
of the GI tract is about 8-12 hours, the maximum half-life for absorption should be 
approximately 3-4 hours; otherwise, the device will pass out of the potential 
absorptive regions before drug release is complete. Thus corresponds to a minimum 
apparent absorption rate constant of 0.17-0.23h to give 80-95% over this time 
period. Hence, it assumes that the absorption of the drug should occur at a relatively 
uniform rate over the entire length of small intestine  
Metabolism: 
Drugs those are significantly metabolized before absorption, either in the 
lumen or the tissue of the intestine, can show decreased bioavailability from slower-
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releasing dosage form. Hence criteria for the drug to be used for formulating 
Sustained-Release dosage form is 
 Drug should have low half-life (<5 hrs.)  
 Drug should be freely soluble in water.  
 Drug should have larger therapeutic window. 
  Drug should be absorbed throughout the GIT  
Even a drug that is poorly water soluble can be formulated in SR dosage form. 
For the same, the solubility of the drug should be increased by the suitable system 
and later on that is formulated in the SR dosage form. But during this the 
crystallization of the drug, that is taking place as the drug is entering in the systemic 
circulation, should be prevented and one should be cautious for the prevention of the 
same. 
Distribution:Drugs with high apparent volume of distribution, which 
influence the rate of elimination of the drug, are poor candidate for oral CR drug 
delivery system. 
Protein Binding:The Pharmacological response of drug depends on unbound 
drug concentration drug rather than total concentration and all drug bound to some 
extent to plasma and or tissue proteins. Proteins binding of drug play a significant 
role in its therapeutic effect regardless the type of dosage form as extensive binding 
to plasma increase biological half-life and thus sometimes CR drug delivery system 
is not required for this type of drug.  
Margin of safety: As we know larger the value of therapeutic index safer is 
the drug. Drugs with less therapeutic index usually poor candidate for formulation of 
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oral CR drug delivery system due to technological limitation of control over release 
rates. 
TI = TD50/ED50 
1.1.5. EFFECT OF RELEASE LIMITING FACTOR ON DRUG RELEASE13,14 
The mechanistic analysis of controlled release of drug reveals that partition 
coefficient; diffusivity; diffusion path thickness and other system parameters play 
various rate determining roles in the controlled release of drugs from either capsules, 
matrix or sandwich type drug delivery systems. 
A. Polymer hydration: It is important to study polymer hydration/swelling process 
for the maximum number of polymers and polymeric combinations. The more 
important step in polymer dissolution include absorption of water in more accessible 
places, rupture of polymer-polymer linking with the simultaneous forming of water-
polymer linking, separation of polymeric chains, swelling and finally dispersion of 
polymeric chain in dissolution medium. 
B. Drug solubility: Molecular size and water solubility of drug are important 
determinants in the release of    drug from swelling and erosion controlled polymeric 
matrices. For drugs with reasonable aqueous solubility, release of drugs occurs by 
dissolution in infiltrating medium and for drugs with poor solubility release occurs 
by both dissolution of drug and dissolution of drug particles through erosion of the 
matrix tablet.  
C. Solution solubility: In view of in-vivo (biological) sink condition maintained 
actively by hem perfusion, it is logical that all the in vitro drug release studies 
should also be conducted under perfect sink condition. In this way a better 
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simulation and correlation of in vitro drug release profile with in-vivo drug 
administration can be achieved. It is necessary to maintain a sink condition so that 
the release of drug is controlled solely by the delivery system and is not affected or 
complicated by solubility factor. 
D. Polymer diffusivity:The diffusion of small molecules in polymer structure is 
energy activated process in which the diffusant molecules moves to a successive 
series of equilibrium position when a sufficient amount of energy of activation for 
diffusion Ed has been acquired by the diffusant is dependent on length of polymer 
chain segment, cross linking and crystallanity of polymer. The release of drug may 
be attributed to the three factors viz, 
i. Polymer particle size  
ii. Polymer viscosity  
iii. Polymer concentration 
i. Polymer particle size: Malamataris stated that when the content of hydroxyl 
propyl methylcellulose is higher, the effect of particle size is less important on the 
release rate of propranolol hydrochloride, the effect of this variable more important 
when the content of polymer is low. He also justified these results by considering 
that in certain areas of matrix containing low levels of hydroxyl propyl 
methylcellulose led to the burst release.  
ii. Polymer viscosity: Increasing the molecular weight or viscosity of the polymer 
in the matrix formulation increases the gel layer viscosity and thus slows drug 
dissolution.  
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iii. Polymer concentration: An increase in polymer concentration causes an 
increase in the viscosity of gel as well as formulation of gel layer with a longer 
diffusional path. This could cause a decrease in the effective diffusion coefficient of 
the drug and therefore reduction in drug release.  
E. Thickness of polymer diffusional path: The controlled release of a drug from 
both capsule and matrix type polymeric drug delivery system is essentially governed 
by Fick’s law of diffusion:   
J = D dc/dx 
Where, J is flux of diffusion across a plane surface of unit area D is 
diffusibility of drug molecule, dc/dx is concentration gradient of drug molecule 
across a diffusion path with thickness dx.  
F. Thickness of hydrodynamic diffusion layer: It was observed that the drug 
release profile is a function of the variation in thickness of hydrodynamic diffusion 
layer on the surface of matrix type delivery devices. The magnitude of drug release 
value decreases on increasing the thickness of hydrodynamic diffusion layer. 
G. Drug loading dose:The loading dose of drug has a significant effect on resulting 
release kinetics along with drug solubility. The effect of initial drug loading of the 
tablets on the resulting release kinetics is more complex in case of poorly water 
soluble drugs, with increasing initial drug loading the relative release rate first 
decreases and then increases, whereas, absolute release rate monotonically increases. 
In case of freely water soluble drugs, the porosity of matrix upon drug depletion 
increases with increasing initial drug loading. This effect leads to increased absolute 
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drug transfer rate. But in case of poorly water soluble drugs another phenomenon 
also has to be taken in to account.  
H. Surface area and volume: The dependence of the rate of drug release on the 
surface area of drug delivery device is well known theoretically  and experimentally. 
Both the in vitro and in vivo rate of the drug release, are observed to be dependent 
upon surface area of dosage form. Siepman et al. found that release from small tablet 
is faster than large cylindrical tablets. 
I. Diluents’ effect: The effect of diluents or filler depends upon the nature of 
diluents. Water soluble diluents like lactose cause marked increase in drug release 
rate and release mechanism is also shifted towards Fickian diffusion; while insoluble 
diluents like dicalcium phosphate reduce the Fickian diffusion and increase the 
relaxation (erosion) rate of matrix. The reason behind this is that water soluble filler 
in matrices stimulate the water penetration in to inner part of matrix, due to increase 
in hydrophilicity of the system, causing rapid diffusion of drug, leads to increased 
drug release rate. 
J. Additives: The effect of adding non-polymeric excipients to a polymeric matrix 
has been claimed to produce increase in release rate of hydro soluble active 
principles. These increases in release rate would be marked if the excipients are 
soluble like lactose and less important if the excipients are insoluble like tricalcium 
phosphate. 
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Table 1 : Classification of sustained/controlled system 
Type of system Rate-controlled mechanism 
Diffusion controlled  
 Reservoir system 
 Monolithic system 
 
Diffusion through membrane 
Water penetration controlled 
Osmotic system 
Swelling system 
Transport of water through semi 
permeable membrane 
Water penetration in to glossy 
polymer 
Chemical control 
Monolithic system 
Pendent system 
Ion exchange resins 
Surface erosion or Bulk erosion 
Hydrolysis of pendent group and 
diffusion from bulk polymer 
Exchange of Acidic or Basic drugs 
with the ions present on resins. 
Regulated system 
Magnetic ultrasound 
External application of magnetic field 
or ultrasound to device 
 
1.1.6. PHARMACODYNAMIC CHARACTERISTICS OF THE DRUG 
1. Therapeutic Range: 
A drug candidate for controlled/sustained delivery system should have a 
therapeutic range wide enough such that variations in the release rated do not release 
in a concentration beyond this level. 
2. Therapeutic Index (TI): 
The release rate of drug with narrow therapeutic index should be such that 
the plasma concentration attend is within the therapeutically safe and at effective 
range. This is necessary becouse such drug have toxic concentration nearer to their 
therapeutic range. A drug with short half – life and narrow therapeutic index should 
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be admininistrated more. Frequently than twice a day. Once must also considered 
the activity of the drug metabolites since controlled delivery system controls the 
only the release of parent drug but not its metabolism. 
3. Plasma concentration-Response relationship: 
Drug such as Reserpine, whose pharmacological activity is independent of 
its concentration,or poor candidates for controlled release system.3 
1.1.7. DRUG SELECTION FOR ORAL SUSTAINED/CONTROLLED DRUG 
DELIVERY SYSTEMS 
The biopharmaceutical evaluation of a drug for potential use in 
sustained/controlled rele1ase drug delivery systems requires knowledge on the 
absorption mechanism of the drug form the G.I tract, the general absorbability, the 
drug’s molecular weight, pKa, solubility at different pH and apparent partition 
coefficient. 
Table2: Parameter for Drug selection15 
Parameter Preferred value 
Molecular weight/size <100 
Pka Non ionized moiety > 0.1% at pH 1 to pH 7.8 
0.1 %Solubilty > 0.1µg/ml for pH 1 to pH 7.8 
Release Should not be influenced by pH and enzymes 
Apparent partition coefficient High 
General absorbability From all G.I segments 
Absorption mechanism Diffusion 
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The pharmacokinetic evaluation requires knowledge on drugs elimination half-life, 
Total clearance, Absolute bio availability, possible first pass effect and the desired 
study concentration for peak and trough. 
Table 3: Pharmacokinetic parameter for drug selection 
Parameter Comment 
Elimination half-life Preferably between 0.5 and 8 hrs 
Elimination Rate constant Required for design 
Apparent volume of distribution Vd The larger Vd 
Total clearance And MEC, the larger will be the required 
dose size 
Therapeutic concentration Cssav Should not be dose dependent 
Absolute bio-availability The lower Cssav and smaller Vd, loss 
among of drug required 
Intrinsic absorption rate Should be 75% or more Must be greater 
than release rate 
Toxic concentration A part of the value of MTC and MEC 
safer the dosage forms. Also suitable for 
drugs with very short half life 
  
1.1.8. CLASSIFICATION OF MATRIX TABLETS:  
On the Basis of Retardant Material Used: Matrix tablets can be divided in to 5 types.  
1. Hydrophobic Matrices (Plastic matrices):16 
In this method of obtaining sustained release from an oral dosage form, drug 
is mixed with an inert or hydrophobic polymer and then compressed in to a tablet. 
Sustained release is produced due to the fact that the dissolving drug has diffused 
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through a network of channels that exist between compacted polymer particles. 
Examples of materials that have been used as inert or hydrophobic matrices include 
polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and their 
copolymers.  
2. Lipid Matrices: 17 
These matrices prepared by the lipid waxes and related materials. Drug 
release as pore diffusion and erosion. Carnauba wax in combination with stearyl 
alcohol or stearic acid has been utilized for retardant base for many sustained release 
formulation. 
3. Hydrophilic Matrices: 18 
These systems are called swellable controlled release systems. The polymers 
used in the preparation of hydrophilic matrices are divided in to three broad groups,  
A. Cellulose derivatives: Methylcellulose 400 and 4000cPs, Hydroxyethylcellulose; 
Hydroxypropylmethylcellulose (HPMC) 25, 100, 4000 and 15000cPs; and Sodium 
carboxymethylcellulose.  
B. Non cellulose natural or semi synthetic polymers: Agar-Agar; Carob gum; 
Alginates; Molasses; Polysaccharides of mannose and galactose, Chitosan and 
Modified starches.  
Polymers of acrylic acid : Carbopol-934, the most used variety.  
3. Biodegradable Matrices:18 
They are biologically degraded or eroded by enzymes generated by 
surrounding living cells or by non enzymatic process in to oligomers and monomers 
Chapter 1  Introduction 
 
Dept. of Pharmaceutics 17 JKK Nattraja College of Pharmacy 
that can be metabolized or excreted. Examples are natural polymers such as proteins 
and polysaccharides; modified natural polymers; synthetic polymers such as 
aliphatic poly (esters) and poly anhydrides. 
4. Mineral Matrices:18 These consist of polymers which are obtained from various 
species of seaweeds. Example is Alginic acid  
On the Basis of Porosity of Matrix: 19, 20 
Matrix system can also be classified according to their porosity and 
consequently, Macro porous; Micro porous and Non-porous systems can be 
identified:  
1. Macro porous Systems:  
In such systems the diffusion of drug occurs through pores of matrix, which 
are of size range 0.1 to 1 µm. This pore size is larger than diffusant molecule size. 
2. Micro porous System:  
Diffusion in this type of system occurs essentially through pores. For micro 
porous systems, pore size ranges between 50 – 200 A°, which is slightly larger than 
diffusant molecules size.  
3. Non-porous System: 
Non-porous systems have no pores and the molecules diffuse through the 
network meshes. In this case, only the polymeric phase exists and no pore phase is 
present. 
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1.1.9. POLYMERS USED IN MATRIX TABLET: 21, 22 
Hydro gels: 
Polyhydroxyethylemethylacrylate (PHEMA),Cross-linked polyvinyl alcohol 
(PVA), Cross-linked polyvinyl pyrrolidone (PVP),  Polyethylene oxide (PEO),  
Polyacrylamide (PA)  
Soluble polymers: 
Polyethyleneglycol (PEG), polyvinyl alcohol (PVA) 
Polyvinylpyrrolidone (PVP), Hydroxypropyl methyl cellulose (HPMC)  
Biodegradable polymers: 
Polylactic acid (PLA), Polyglycolic acid (PGA) , Polycaprolactone (PCL) 
Polyanhydrides, Polyorthoesters 
Non-biodegradable polymers: 
Polyethylene vinyl acetate (PVA) , Polydimethylsiloxane (PDS) 
Polyether urethane (PEU), Polyvinyl chloride (PVC) 
Cellulose acetate (CA), Ethyl cellulose (EC)  
Mucoadhesive polymers: Polycarbophil, Sodium carboxymethyl cellulose, 
Polyacrylic acid, Tragacanth, Methyl cellulose, Pectin  
Natural gums : Xanthan gum, Guar gum, Karaya gum, Locust bean gum. 
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1.2. Types of controlled released system23-26 
A) Diffusion controlled release system: 
Diffusion process shows the movement of the drug molecule from a region 
of a higher concentration to lower concentration. The flux J (in amount/area-time), 
across a membrane in the direction of decreasing concentration is given by Fick’s 
law. 
J = -D dc/dx 
D = diffusion coefficient in area/time 
Dc/dx = change of concentration ‘c’ with distance ‘x’ 
In common form, when a water insoluble membrane encloses a core of drug ,it must 
diffuse through the membrane, the drug release rate dm/dt is given by 
dm/dt = ADK ∆ C/L 
where A = area 
k = partition coefficient of drug between the membrane and drug core 
L = diffusion path length 
∆c = concentration difference across the membrane. 
i) Reservoir type: 
 In the system, a water insoluble polymeric material encases a core drug. 
Drug will partition in to the membrane and exchange with the fluid surrounding the 
particle or tablet.Additional drug will enter the polymer, diffuse to the periphery and 
exchange with the surrounding media. 
Chapter 1  Introduction 
 
Dept. of Pharmaceutics 20 JKK Nattraja College of Pharmacy 
Advantages: zero order delivery possible,release rate depend on type of polymer 
Disadvantages: High molecular weight compounds difficult to deliver,potential 
toxic if system fails. 
ii)      Matrix system: 
A solid drug is dispersed in an insoluble matrix and the rate of release of 
drug is dependent on the rate of drug diffusion and not on the rate of solid 
dissolution. 
Higuchi has derived the appropriate equation for drug release for this system 
Q = Dε/T [ 2 A – εCs] Cst1/2 
Where; 
Q = weight in gms of drug released per unit area of surface at time t 
D = Diffusion coefficient of drug in the release medium 
ε = porosity of th matrix 
Cs = solubility of drug in release medium 
T = Tortuosity of the matrix 
A = concentration of drug in the tablet, as gm/ml 
Advantages: Easier to produce, can deliver high molecular weight compounds. 
Disadvantages: Cannot provide zero order release, required removing reaming 
matrix. 
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A third possible diffusional mechanism is the system where a partially 
soluble membrane encloses a drug core.Dissolution of part of membrane allows for 
diffusion of the constrained drug through pores in the polymer coat. 
The release rate can be given by following equation:- 
Release rate = AD/L = [ C1 – C2] 
A = area 
C1 = Concentration in the core 
C2 = Drug concentration in the surrounding medium 
L = diffusional path length 
Diffusion process involves two approaches first matrix and drug diffuses out 
of the matrix to the surrounding pool for ultimate absorption. Second approach 
involves enclosing the drug particle with a polymer coat. 
B) Dissolution controlled release system: 
A drug with a slow dissolution rate is inherently sustained and for those 
drugs with high water solubility, one can decrease dissolution through appropriate 
salt or other derivative formation. 
i) Reservior type: 
Drug is coated with a given thickness coating, which is slowly dissolved in 
the contents of gastrointestinal tract. By altering layers of drug with the rate 
controlling coats pulsed delivery can be achieved. An alternative method is to 
administer the drug beads that have coating of different thickness. Since the beads 
have different coating thickness, their release occurs in a progressive manner. 
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Cellulose nitrate phthalate was synthesized and used as an enteric coating agent for 
acetyl salicylic acid tablets. 
ii) Matrix type: 
The most common type of dissolution controlled release dosage form. It can 
be either drug impregnated sphere or drug impregnated tablet, which will be 
subjected to slow erosion. 
Two types of dissolution – controlled pulsed delivery systems: 
a) Single bead – type device with alternating drug and rate- controlling layer 
b) Beads containing drug with differing thickness of dissolving coats. 
C) Methods using Ion - exchange: 
It is based on the formation of drug resin complex formed when a ionic 
solution is kept in contact with ionic resins. The drug from this complex gets 
exchanged in GIT and released with excess of Na+ and cl- present in GIT. 
Resin + - Drug - + Cl – goes to + Cl- + Drug- 
 Resin –Drug+ + Na + goes resin – Na++ Drug 
D) Methods using osmotic pressure: 
A semipermiable membrane is placed around a tablet, particle or drug 
solution that allows transport of water in to the tablet with eventual pumping of drug 
solution out of the tablet through a small delivery aperture in tablet coating. 
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Two types of osmotically controlled release sytems are 
Type A contains an osmotic core with drug 
Type B contains the drug in flexible bag with osmotic core surrounding. 
E) pH – Independent formulations: 
The GIT present some unusual features for the oral route of drug 
administration with relatively brief transit time through the GIT, which constraint 
the length of prolongation, further the chemical environment throughout the length 
of GIT is constraint on dosage form design.Since most drugs are either weak acids 
or bases, the release from controlled release form is pH dependent. However buffers 
such as salts of amino acid, citric acid, Pthalic acid, Phosphoric acid or tartaric acid 
can be added to the formulation, to help to maintain a constant pH there by 
rendering pH independent drug release. 
e.g: Propoxyphene in bufferd controlled release formulation, which 
significantly increase reproductibility. 
F) Alerted density formulations: 
It is reasonable to expect that unless a delivery system remains in the 
victinity of the absorption site until most, if not all of it would have limited utility. 
To this end several approaches have been developed to prolong the residence time of 
drug delivery system in the GIT. 
High density approach: 
In this approach the density of the pellets must exceed that of normal 
stomach content and should therefore be at least 1 – 4 gm/cm3. 
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Low density approach: 
Globular shells which have an apparent density lower than that of GIT fluid 
can be used as a carrier of drug for sustained release purpose. 
1.3. INTRODUCTION TO MIGRANE 
Cluster headache is a relatively rare but extremely debilitating disorder that 
is characterized by the rapid onset of unilateral, periorbital headache that quickly   
escalates to maximum intensity. Patients routinely report the pain of an attack as 
being the most severe they have ever experienced. By the definition of the 
International Headache Society, attacks typically last from 15 to 180 min when left 
untreated and are accompanied by one more cranial autonomic feature such as 
ipsiletaral conjunctiva injection, lacrimation and rhino rhea or nasal congestion27. In 
this case, a rapid onset of pharmacological effect is an often desired from drugs. 
This can effectively be achieved by parenteral Administration, but this method may 
not always be convenient for the patient. Therefore there is growing interest in 
developing new, non-parenteral, reliable and convenient dosage forms using 
administration routes where a rapidly dissolved drug is immediately absorbed into 
the systemic circulation. 
Zolmitriptan is a second-generation triptan prescribed for patients with 
migraine attacks, with and without an aura, and cluster headaches. It has a selective 
action on serotonin receptors and is very effective in reducing migraine symptoms, 
including pain, nausea and photo- or phonophobia. It is currently available as a 
conventional tablet, an oral disintegrating tablet and anasal spray (2.5 mg and 5 mg 
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per dose). The absolute bioavailability of zolmitriptan is up to 40% for both oral and 
nasal dosage forms.28 
Vasodialtion of blood leads headache were zolmitriptan drug acts on 5 
HT1B& 5HT 1D Receptors and constricts the blood vessel thus it prevents headache. 
Table4:Physico characteristics of zolmitriptan29 
S.No Parameters Description 
1 Molecular formula C16H21N3O2 
2 Molecular weight 287.3 
3 Physical state of powder White crystalline powder 
4 Melting point 136-141 ºC 
5 Solubility Solubility in water and 
6 Dissociation constant pKa 9.6 
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2.  LITERATURE REVIEW 
ziya bayrak et al., (2011)30 prepared sublingual zolmitriptan tablets.In this study, 
using different mucoadhesive polymers such as hydroxypropyl methyl cellulose, 
chitosan and sodium carboxy methyl cellulose at a concentration range of 0.5–5%. 
The tablets disintegrated rapidly, and dissolution tests revealed that zolmitriptan was 
dissolved from the formulation within the compendial limits and shows 
concentration range of polymers is in acceptable limit. It was also concluded that 
microcrystalline cellulose, spray-dried lactose and sodium starch glycolate are the 
appropriate excipient and formulated in good proportions. In-vivo studies indicated 
that formulation containing 5% chitosan has the maximum Cmax and AUC and 
minimum tmax values (p < 0.05). As a result, sublingual tablet administration of 
zolmitriptan formulated with appropriate excipients and especially with chitosan 
seems promising alternative to traditional routes. 
Golam kibria et al.,(2008) 31  Prepared the alfuzosin matrix tablets. The aim of the 
study was the development and in vitro evaluation of a controlled release dosage 
form of a freely soluble weakly basic drug (alfuzosin hydrochloride). Binary mixer 
of one hydrophilic polymer (hydroxypropyl methylcellulose) and one hydrophobich  
polymer (ethyl cellulose) was used in tablets prepared by direct compression.The 
percent drug released at 1, 6, 12, and 20 h were selected as response.. Dissolution 
data were fitted to zero order, first order, and Higuchi’s release kinetics to evaluate 
kinetic data. According to Korsmeyer's equation drug release followed both 
diffusion and erosion mechanism in all cases. Drug release was different from three 
fillers (microcrystalline cellulose, lactose and dibasic calcium phosphate. 
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Gurpreet Arora et al.,(2011)32 Developed, oral controlled release mucoadhesive 
matrix tablets of domperidone as model drug using natural mucoadhesive material 
myrrh oleo gum resin (MOGR).The tablets were formulated with the natural 
polymer in different concentration (5, 10, 15 and 20 % w/w) employing direct 
compression technology. The prepared batches were evaluated for tablet prepared 
batches. The tensile strength increases from 0.973±0.09 to 1.687±0.11 MN/m2 and 
mucoadhesive strength from19.868 to 49.778 N with the increase in natural polymer 
concentration from 5 to 20 % (M1 to M4). The release kinetic and mechanism of 
release were calculated by fitting in-vitro release data in various models 
demonstrating that release follows zero order and Hixson Crowell cube root law. 
The release exponent (n) ranges in between 0.5889 to 0.7389 indicating multiple 
release mechanisms possibly the combination of diffusion and erosion. These 
research outcomes clearly specify the potential of MOGR to be used as binder, 
release retardant and mucoadhesive natural material in tablet formulations. 
R. L. C. Sasidhar et al.,(2009) 33  Formulated Losartan Potassium as oral controlled 
release matrix tablets by using poly(ethylene oxides) {Polyox WSR 303}.And 
investigated the influence of polymer level and type if fillers namely lactose [soluble 
filler], microcrystalline cellulose and anhydrous dibasic calcium phosphate 
[insoluble fillers] on the release rate and mechanism of Losartan Potassium from 
matrix tablets prepared by direct compression process. Higher polymeric content in 
the matrix decreased the release rate. At lower polymeric level the rate and extent of 
drug release was elevated. On the other hand, replacement of lactose with anhydrous 
dibasic calcium phosphate and microcrystalline cellulose have significantly retarded 
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the release rate of Losartan Potassium. The formulations F3 & F6 are considered to 
be best formulations and can further evaluated for In-vivo pharmacokinetic studies. 
Shefaat Ullah Shah et al.,(2009)34 Described the formulation and evaluation of 
controlled release polymeric tablets of Diclofenac Potassium by wet granulation 
method. Formulations having three grades of polymer Ethocel (7P; 7FP, 10P, 10FP, 
100P, 100FP) in several drugs to polymer ratios (10:3 and 10:1) were compressed 
into tablets using wet granulation method. In vitro drug release studies were 
performed using Phosphate buffer (pH 7.4) as a dissolution medium. The similarities 
and dissimilarities of release profiles of test formulations with reference standard 
were checked using f2 similarity factor and f1 dissimilarity factor. 
Mathematical/Kinetic models were employed to determine the release mechanism 
and drug release kinetics. 
Sandip B. Tiwari et al.,(2003) 35 Studied the effect of concentration of hydrophilic 
(hy-droxypropyl methylcellulose [HPMC]) and hydropho-bic polymers 
(hydrogenated castor oil [HCO], ethylcel-lulose) on the release rate of tramadol was 
studied by wet granulation technique, while hydrophobic (wax) matrix tablets were 
prepared by melt granulation technique and in-vitro dissolution studies were 
performed using United States Pharmacopeia (USP) apparatus type II. Hydro-phobic 
matrix tablets resulted in sustained in-vitro drug release (>20 hours) as compared 
with hydrophilic matrix tablets (<14 hours). The presence of ethylcellulose in either 
of the matrix systems prolonged the release rate of the drug. Tablets prepared by 
combination of hydrophilic and hydrophobic polymers failed to prolong the drug 
release beyond 12 hours. The effect of ethylcellulose coating (Surelease) and the 
presence of lactose and HPMC in the coating composition on the drug release was 
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also investigated. Hydrophobic matrix tablets prepared using HCO were found to be 
best suited for modulating the delivery of the highly water- soluble drug, tramadol 
hydrochloride. 
Raja sekharan et al.,(2008)36 Prepared Theophylline controlled release matrix 
tablets with guar gum in two ratios and with three different hardness of 5, 6 and 
7kg/cm
2
. All the formulation showed good flow properties. The compressed tablets 
were evaluated. All the formulations showed compliance with pharmacopial 
standards. There was no interaction between drug, polymer and other excipients. It 
was confirmed by FTIR studies. Among all the formulations F6 (i.e. polymer 
ratio1:2 and hardness 7kg/cm
2) showed prolong release when compare to other 
formulations. The drug release kinetics showed zero order. The optimum 
formulation (F6) was stable when it was stored at 40 + 20 C, 280 + 20 C and at 450 + 
2
0 
C for 6 months.  
R.K.Kar et al., 37 prepared oral controlled release matrix tablets of Zidovudine 
(AZT). Tablets were prepared by direct compression method using various 
proportion of hydrophilic polymer viz; Eudragit RS100 and RL100 along or in 
combination with hydrophobic polymer ethyl cellulose. All evaluation test are 
performed. Dissolution study revealed that either Eudragit RS100 or RL100 
10%,20% w/w of tablet preparations were able to sustain the drug release up to 9 
hours, but 30%, 40% as well as ethyl cellulose combination with 20% and 25% w/w 
of Eudragit RS100 and RL100 were able to sustaining the drug release for 12 hour. 
Mathematical analysis of the release kinetics indicated that the nature of drug release 
from the matrix tablets followed non-Fickian diffusion mechanism. No compatibility 
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was observed between the drug and excipients used in the formulation of matrix 
tablets. The optimized formulation (F13) showed insignificant difference in release 
mechanism as well as release kinetics (P>0.05) when stability study was done for six 
months at 40±2 C and 75±5% RH. 
Mohammad Usman et al.,(2011)38 Prepared Mefenamic acid 200 mg controlled 
release matrices by direct compression and in vitro drug dissolution studies were 
performed to find out the drug release rate and patterns. Methocel was used as rate 
controlling polymer. Also the effect of several co-excipients was investigated on the 
drug release rates during in vitro dissolution studies. Formulated the drug at 4 
different D: P ratios. Phosphate buffer pH 7.2 was used as dissolution medium using 
PharmaTest dissolution apparatus. Several kinetic models were applied to the 
dissolution profiles to determine the drug release kinetics. 
J. Sahoo, et al.,(2008) 39 A hydrophilic matrix-based tablet using different 
concentrations of HPMC K15M or Kollidon®SR was developed using direct 
compression technique to contain 80 mg of propranolol hydrochloride. The resulting 
matrix tablets prepared with HPMC K15M or Kollidon®SR fulfilled all the official 
requirements of tablet dosage forms. Formulations were evaluated for the release of 
propranolol hydrochloride over a period of 12 h in pH 6.8 phosphate buffer using 
USP type II dissolution apparatus. And seen FTIR and DSC test . Tablets were 
exposed to 40 °C/75% of RH in open disc for stability. The in-vitro drug release 
study revealed that HPMC K15 at a concentration of 40% of the dosage form weight 
was able to control the release of propranolol hydrochloride for 12 h, exhibit non-
Fickian diffusion with first-order release kinetics where as at 40% 
Kollidon®SRsame dosage forms show zero-order release kinetics. In conclusion, the 
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in-vitro release profile and the mathematical models indicate that release of 
propranolol hydrochloride can be effectively controlled from a single tablet using 
HPMC K15M or Kollidon®SR. 
HamdyAbdelkader et al.,(2008) 40  Investigated the influence of polymer on 
baclofenac matrix tablets  including hydrogenated castor oil (HCO); Eudragit RS100 
(E-RS100); Eudragit L100 (E-L100), and some fillers namely mannitol [soluble 
filler], Dibasic calcium phosphate dehydrate (Emcompress) and anhydrous dibasic 
calcium phosphate [insoluble fillers] on the release rate and mechanism of baclofen 
from matrix tablets prepared by a hot-melt granulation process (wax tablets) and wet 
granulation process (E-RS100 and E-L100 tablets). Higher polymeric content (40%) 
in the matrix decreased the release rate of drug because of increased tortuosity and 
decreased porosity. At lower polymeric level (20%), the rate and extent of drug 
release was elevated. HCO was found to cause the strongest retardation of drug. On 
the other hand, replacement of Em compress or anhydrous dibasic calcium 
phosphate for mannitol significantly retarded the release rate of baclofen, except for 
E-L100 (pH-dependent polymer). Emcompress surface alkalinity and in-situ 
increase in pH of the matrix microenvironment enhanced the dissolution and erosion 
of these matrix tablets. The prepared tablets showed no significant change in drug 
release rate when stored at ambient room conditions for 6 months. 
Amir Badshah et al.,(2011)41 Developed Controlled-release (CR) matrix tablet of 4 
mg risperidone  using dry granulation–slugging method to improve its safety profile 
and compliance. Model formulations F1, F2, and F3, consisting of distinct blends of 
Methocel® K100 LV-CR and Ethocel® standard 7FP premium, were slugged. Each 
batch of granules (250–1,000 µm), obtained by crushing the slugs, was divided into 
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three portions after lubrication and then compressed to 9-, 12-, and 15-kg hard 
tablets. In-vitro drug release studies were  carried out in 0.1 N HCl (pH 1.2) and 
phosphate buffer (pH 6.8) using a paddle dissolution apparatus run at 50 rpm. The 
CR test tablet, containing 30% Methocel® and 60% Ethocel® (F3) with 12-kg 
hardness, exhibited pH-independent zero-order release kinetics for 24 h. The drug 
release rate was inversely proportional to the content of Ethocel®, while the gel 
layer formed ofMethocel® helped in maintaining the integrity of the matrix. 
Changes in the hardness of tablet did not affect the release kinetics. The tablets were 
reproducible and stable for 6 months at 40±2°C/75±5% relative humidity. 
Risperidone and its active metabolite, 9-hydroxyrisperidone, present in the pooled 
rabbit’s serum, were analyzed with HPLC-UV at λmax 280 nm. There was a good 
association between drug absorption in-vivo and drug release in-vitro (R2=0.7293). 
The successfully developed CR test tablet may be used for better therapeutic 
outcomes of risperidone. 
Ashishbhandari et al.,(2012)42. Designed controlled release matrix tablets of 
Sildenafil citrate is designed by simplex lattice design and evaluating the 
relationship and influence of different content levels of HPMC (Hypromellose), 
Eudragit L100 and Carbopol (Carbomer), in order to achieve a zero-order release of 
Sildenafil citrate. Tablets were prepared by wet granulation process and evaluated 
for different pre and post compression parameter, from these matrix tablets drug 
release was prolonged, leading to achieve an effective therapy with low dosage of 
the drug, to reduce the frequency of medication. 
Silvina A.et al.,(2002) 43 Formulated HPMC matrix tablets of Diclofenac Sodium 
using microcrystalline cellulose (MCC), starch, and lactose by wet granulation 
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process. The USP paddle used to perform the dissolution profiles carried out in 900 
mL 0.1 N HCl, and phosphate buffer. There was no significant difference in drug 
release between the hydrophilic matrices when the HPMC concentration was 
modified in low percentage. Release kinetics of Diclofenac Sodium from these 
swollen matrices was principally regulated by starch (17%) or lactose (17%), even 
on the presence of MCC. When starch (8.5%) and lactose (8.5%) were mixed at 
lower concentration in a ratio 1:1, MCC (5% or 7,5%) appeared to control the drug 
release. The data obtained proved that the formulations are useful for a sustained 
release of Diclofenac, due to the percentage released after 8 hours is nearly to 70%.  
G. Sridhar et al.,(2012) 44 Formulated buccal patches of zolmitriptan by solvent 
casting method using HPMC E 15, aloe vera, Na CMC and eudragit RS100 as film 
forming polymers. The developed patches were evaluated for the thickness, folding 
endurance, bioadhesion strength, in-vitro residence time, mucoadhesive strength, in 
vitro drug release studies and ex-vivo drug permeation characteristics. Formulation 
F10 (contains HPMC E 15 &eudragit RS 100) has shown optimum ex-vivo 
mucoadhesion strength (19.4±0.9 g), in vitro residence time (6.0±0.14 hrs), in vitro 
drug release (75.06±1.12%) for 8hrs and satisfactory surface PH (6.8±0.02), ex vivo 
drug permeation (94.04±1.04%). The IR spectroscopic studies revealed that there is 
no evidence for chemical interaction between drug and polymers. 
Chapter 3 Drug Profile 
 
Dept. of Pharmaceutics 34 JKK Nattraja College of Pharmacy 
3. DRUG PROFILE 
3.1. ZOLMITRIPTAN 45, 46, 47, 48 
 Product name : ZOLMITRIPTAN 
 Chemical name   : (4S)-4-({3-[2-(dimethyl amino)ethyl]-1H-indol- 
  5- yl}methyl)-1,3-oxazolidin-2-one 
 Molecular formula     : C16H21N3O2 
 Molecular weight      : 287.3 
Structure  of   Zolmitriptan: 
 
PHARMACOKINETICS 
 Absorption : approximately 40% 
 Distribution : 8.4± 3.3 L/kg 
 Metabolism      : Hepatic 
 Elimination : renal and fecal 
 Protein binding     : 25% 
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 Half life : 3 hours 
 Solubility         : readily soluble in water, freely soluble in 0.1 N Hcl 
 Dose : 2.5mg, 5mg 
 Available trade names  : AscoTop, Zomig, Zomig, Rapimelt, Zomigon 
 Adverse drug reaction : Myocardial infarction, hypoesthesia, parahtesia,B.P 
 Adverse interactive drug 
Storage: Store between 200C – 250C.Protect from sun light. 
Dosage form: Dose 2.5mg or 5 mg of tablet or powder form. Not recommended for            
pediatric and neonates 
Overdose/Toxicity: Symptoms include low B.P, confusion, agitation, sweating, 
convulsion, chest pain, heart pain. 
Warnings:should not be used within 24 hours of treatment with another 5-HT1 
agonist, or an ergotamine-containing or ergot-type medication like 
dihydroergotamine or methysergide, and should not be administered to patients with 
hemiplegic or basilar migraine. 
Mechanism of action: 
It has a selective action on serotonin receptors  and is very effective in 
reducing migraine symptoms, including pain, nausea and photo or phonophobia. 
Vasodialtion of blood leads headache were Zolmitriptan drug acts on 5 HT1B& 5HT 
1D Receptors and constricts the blood vessel. 
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3.2 POLYMER PROFILE: 
HYDROXYPROPYL METHYL CELLULOSE [HPMC] 49, 50 
1. Nonproprietary name: 
BP : Hypromellose 
Jp : Hydroxy propyl methyl cellulose 
PhEur : hypromellosem 
USP : hypromellose 
2. Synonyms: 
Benecel MHPC; E464;Methocel;Methyl Cellulose Propylene Glycol Ether; 
Methyl Hydroxyl Propyl Cellulose; Metolose; tylopur. 
3 Chemical name: cellulose hydroxypropylmethylether. 
4 CAS registry number: [9004-65-3] 
5. Empircal formula: CH 3 CH (OH)CH2 
6. Structural formula: 
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7. Molecular weight: 10000 to 1500000 
8. Functional category: 
Coating agent; film-former; rate-controlling polymer for controlled release; 
stabilizing agent; suspending agent; tablet binder; viscosity – increasing agent. 
9. Description: It is odorless and tasteless, white or creamy-white fibrous and 
granular powder. 
10. Typical properties: 
Acidity/ Alkalinity: pH is 5.5- 8.0 from a 1 % w/w aqueous solution. 
Density:    Bulk – 0.341 gm/cm3 
                 Tapped - 0.557 gm/cm3 
True - 1.326 gm/cm3 
Melting point: Browns at 190 – 200 0C, chars at 225-230 0 C. Glass transistion 
temperature is 170- 180 0 C. 
Moisture content: It absorbs moisture from the atmosphere, the amount of 
water absorbed depends up on the initial moisture content, the temperature and 
relative humidity of the surrounding air. 
Solubility: Soluble in cold water forming a colloidal solution; practically insoluble 
in chloroform, ethanol (95%) and ether, but soluble in mixture of ethanol and 
dichloro methane, mixture of methanol and dichloro methane, and mixture of water 
and alcohol. Certain grades of hypromellose are soluble in aqueous acetone 
solutions, mixture of dichloromethane and propan-2-ol and other organic solvents. 
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Viscosity (dynamic): A wide range of viscosity types are commercially available. 
Aqueous solution are most commonly prepared, although hypromellose may also be 
dissolved in aqueous alcohol such as ethanol and propan-2-ol provided the alcohol 
content is less than the 50 % w/w. Dichloromethane and ethanol mixture also a\may 
be used to prepare viscous hypromellose solution. Solution prepared using organic 
solvents tend to be more viscous and concentration also produces more viscous 
solution. The designations of the HPMC refer to viscosities in 2% aqueous solution, 
for example K4M has a viscosity of 4000 mPas and K15M has a viscosity of 15000 
m pas. 
11. Applications of polymer in pharmaceutical formulation or technology 
 Uses oral, ophthalmic and topical pharmaceutical formulations.  
 Emulsifier, Suspending Agent, and Stabilizing Agent In Topical Gels And 
Ointments. 
 As a protective colloid, it can prevent droplets and particles from coalescing or 
agglomerating, thus inhibiting the formation of sediments.  
12. Incompatabilites: 
It is incompatibile with some oxidizing agents. Since it is non ionic, it will 
not complex with metallic salts or with ionic organics to form insoluble precipitates. 
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3.2 CELLULOSE ACETATE PTHALATE (CAP) 51 
Non proprietary Names: 
 BP : Cellacephate 
 PhEur     : Cellulosiacetaspthalas 
 USPNF   : Cellulose acetate phthalate 
Synonyms: 
     Acetyl pthalyl cellulose; CAP ; cellacefate; cellulose acetate hydrogen 1,2 
benzenedicarboxylate; cellulose acetate hydrogen phthalate; cellulose acetate 
monopthalate; cellulose acetopthalate; cellulose acetylpthalate. 
Chemical Name: Cellulose, acetate, 1, 2-benzenedicarboxylate 
 Structure: 
 
Functional category: coating agent 
Melting point: 192 0C.Glass transition temperature is 160 – 170 0C 
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Applications in pharmaceutical formulation or Technology 
 Used as enteric film coating material or as matrix binder for tablets 
 It is used as a pharmaceutical excipient to solid dosage forms either by coating 
from organic or aqueous solvent systems,or by direct compression 
 It is used in concentration of 0.5 to 0.9%of the core weight. 
 Adittion of plasticizers improve water resistance more when compared to   the 
cellulose alone. 
 It is also used as other coating form in combination with other agents to 
control drug release. 
Description:  
It is a hygroscopic, white, free flowing powder or colorless flakes. It is 
tasteless and odorless, or may have a slight odor of acetic acid. 
Typical properties: 
Hygroscopicity: 
Cellulose acetate phthalate is hygroscopic and precautions are necessary to 
avoid excessive absorption of moisture. 
Solubility: Practically insoluble in alcohols, chlorinated hydrocarbons, 
hydrocarbons and water; soluble in cyclic ethers, esters, ether alcohols, ketones and 
certain solvent mixtures. Also soluble in certain buffered aqueous solution at greater 
than pH 6. 
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Stability and storage condition: 
It hydrolyzes slowly under prolonged adverse conditions such as high 
temperature and humidity, with a resultant increase in free acid content, viscosity 
and odor of acetic acid. If its moisture content is above 6 % w/w, fairly rapid 
hydrolysis occurs. However acetate phthalate is stable if stored in a well closed 
container in a cool dry place. 
Incompatibilities : 
Cellulose acetate phthalate incompatible with ferrous sulfate, ferric chloride, 
silver nitrate, sodium citrate, aluminum sulfate, calcium chloride, mercuric chloride, 
barium nitrate, basic lead acetate, and string oxidizing agents such as strong alkalis 
and acids. It should be noted that one carboxylic acid group of the pthalic acid 
moiety remains un esterified and free for interactions. Accordingly, in compatibility 
with acid sensitive drug may occurs. 
Safety:Regarded as free from adverse  effects and nontoxic. 
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LACTOSE MONOHYDRATE
Non – proprietary names:
 BP : Lactose 
 PhEur: Lactose Monohydrate
 Jp: Lactose Hydrate
 USP_NF : Lactose Monohydrate 
Synonyms: CapsuLac; Lactochem; Lactosummonohydricum; Monohydrate; 
pharmatose; Prismalac, Sach Lac; SorboLac; SpheroLac;SuperTab 30GR; 
Tablettose. 
Chemical Name: O-b-D-
Empirical formula: C12H
Molecular weight: 360.31
Structural formula: 
Description: 
In the solid state, Lactose appears as various isomeric forms, depending on 
the crystallization and drying condit
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anhydrous and a lactose anhydrous. The stable crystalline forms of lactose are        
α-lactose monohydrate, β-lactose anhydrous and stable α-lactose anhydrous. it 
occurs as white to off white crystalline particles or powder. Lactose is odorless and 
slightly sweet tasting; α-lactose is approximately 20% as sweet as sucrose, white β-
lactose is 40% sweet. 
Functional category: 
Dry powder inhaler carrier; lyophilization aid; tablet binder; tablet and 
capsule diluents and filler. 
Typical Properties: 
Loss on drying: Typically 0.2 % for Monohydrate 80M, Monohydrate Impalpable; 
and 0.1 – 0.2 % for Meggle products. 
Melting point: 201-202 0C (for dehydrated α- lactose monohydrate) 
Moisture content: Lactose monohydrate contains approximately 5% w/w water of 
crystallization and normally has a range 4.5% - 5.5% w/w water content. 
Hygroscopicity:Povidone is very Hygroscopic significant amount of moisture being 
absorbed at low relative humidities. 
Particle size distribution: 90 > 50µm, 50%> 100 µm,5%>200 µm in size for 
kollidon 25/30; 90%>200 µm,250 µm in size for kollidon 90. 
Solubility: solvent solubility at 208 0 unless otherwise stated, chloroform practically 
insoluble, Ethanol practically insoluble, Ether Practically insoluble. 
Tensile Strength : 2.987 MPa ( at compression pressure 189.5 MPa); 2.517 MPa. 
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Density : 1.545 fm/cm3 
Storage and stability: Mold growth may occur under humid conditions (80% 
relative humidity and above). Lactose may develop a brown coloration on storage, 
the reaction being accelerated by warm, damp conditions. The purities of different 
lactose’s can vary and color evaluation may be important, particularly if white 
tablets are being formulated. solution shows mutarotation. it should be stored in a 
well- closed container in a cool, dry place. 
Safety: Adverse reactions to lactose are largerly attribute to lactose in tolerance, 
which occurs in individuals with a deficiency of the intestinal enzyme lactase. 
Applications in Pharmaceutical Formulations or Technology: 
 Widely used as a filler and more limited extent in lyophilized products and in 
infants formulation. 
 It is used as diluents in Dry- powder inhlation. 
 Lactose is added to freeze dried solutions to increase plug size and aid 
cohesion.with the combination of sucrose used as sugar coating solution. 
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ETHYL CELLULOSE [EC]: 51 
Ethyl cellulose (EC) is available under the brand name Ethocel 7 cps was 
sourced from DOW Chemicals Company. The chemical name of ethyl cellulose is 
Cellulose ethyl ether (CAS no. 9004-57-3). The product has approved regulatory 
status as per USP-NF, Ph.Eur. JP and BP. It is a derivative of cellulose in which 
some of the hydroxyl groups on the repeating glucose units are converted into ethyl 
ether groups. 
Bulk density: 
0.3 – 0.4 gm/cm3 
Structure: 
 
It is available as free flowing powder, white or light tan in color with a 
density of 0.4g/cm2. It is practically insoluble in water, glycerol and propane-1-2-
diol, but soluble in organic solvents. Ethyl cellulose containing 46-48% of ethoxyl 
group is freely soluble in ethanol, methanol, chloroform and ethyl acetate. Neutral to 
litmus, with LOD not more than 3%. It is mainly used as a thin-film coating 
material. In addition to being useful in a variety of pharmaceutical applications. It 
also features a fine particle (FP) range for use in extended release matrix surface 
area. This flexibility is further enhanced by the ability to modify release profiles 
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when ETHOCEL™ is used in combination with water-soluble excipients such as 
Colorcon’s METHOCEL™ premium cellulose ethers175, 176.  Ethyl cellulose is a 
stable, slightly hygroscopic material. It is chemically resistant to alkalies. Ethyl 
cellulose is prone to oxidative degradation in presence of UV light. Ethyl cellulose 
should be stored at a temperature not exceeding 32 0 C in a dry area and away from 
heat . 
TALC : 
1. Non – proprietary names: 
 BP : Purified talc 
 PhEur: Talcum 
 Jp: Talc 
 USP_NF : Talc 
2. Synonyms: 
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Luzenacpharma;magenisium hydrogen metasilicate; magsilosmanthus;Magsil star; 
powdered talc; Purified French chalk; purtalc; soap stone; steatite; Superiore. 
3. Chemical Name and CAS Registry Number:Talc [ 14807-96-6 ] 
4. Empirical formula: Mg6(Si2O5)4(OH)4 
5. Functional category: 
Anticaking agent; glidant; tablet and capsule diluents; tablet and capsule; lubricant 
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6. Typical Propertes: Acidity/alkalinity: 
pH = 7-10  for a 20% w/v aqueous dispersion 
Hardness: 1.0-1.5 
Moisture content: 
Talc absorbs insignificant amounts of water at 25 0 C and relative humidites 
up to about 90%. 
Particle size distribution: 
Varies with the source and grade of material. Two typical grades are ≥ 99% 
through a 74 µm (  # 200 mesh) or ≥ 99% trough 44 µm ( #325 mesh) 
Refractive index: n20,D = 1.54 – 1.59 
Solubility: Practically insoluble in dilute acids and alkalis, Organic solvents and 
water 
Specific gravity: 2.7-2.8 
Specific surface area: 2.41 –  2.42 m2/g. 
7. Description: Talc is very fine, white to grayish –white, odorless, impalpable, 
unctuous, crystalline Powder. It adheres readily to the skin and is soft to touch and 
free from grittiness.  
8. Stability and storage Conditions: 
Talc is a stable and may be sterilized by heating at 160 0 C for not less than 1 
hour or to ethylene oxide or gamma irridation. Talc should be stored in a well- 
closed container in a cool, dry place. 
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9. Applications in Pharmaceutical Formulation or Technology: 
Talc was once widely used in oral solid dosage formulations as a lubricant 
and diluents, dissolution retardan although today it is less commonly used.  
MAGNESIUM STEARATE 
1. Non – proprietary names: 
 BP : Magnesium stearate 
 PhEur: Magnesiistaras 
 Jp: Magnesium steriate 
 USP_NF : Magnesium steriate 
2.Synonyms: 
Magnesium octadecanoate 
Octadecanoic acid, Magnesium salt 
Stearic acid, Magnesium salt 
3. Chemical Name and CAS: 
Chemical name and CAS registry number octadecanoic acid magnesium salt 
and [ 557-04-0 ]. 
4. Empirical Formula and Molecular weight: 
C36H70MgO4  and 591.34 
5. Functional Category: 
Tablet and capsule lubricant 
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6. Typical Properties: 
Crystaline forms 
High-purity magnesium stearate has been isolated as a Tri hydrate, a Di hydrate and 
An hydrate. 
Bulk denity: 0.159 gm/cm3 
Tapped density: 0.286 gm/cm3 
True density:  1.092 gm/cm3 
Flash point: 250 0 C 
Flowability: Poorly flowing, coahesive powder 
Melting range: 
 117-150 0 C ( commercial samples) 
 126-130 0 C ( high purity magnesium stearate) 
Solubilty: 
Practically insoluble in ethanol, ethanol 95%, ether and water slightly soluble 
in warm benzene and warm ethanol 95% 
Specific surface area: 
1.62-14.8 m2/gm 
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7. Stability and storage conditions: 
Magnesium stearate is stable and should be stored in a well closed container 
in a cool, dry place. 
8. Incompatibilities: 
Incompatibile with strong acid, alkalis and Iron salts. Avoid mixing strong 
oxidizing materials. Magnesium stearate cannot be used in products containing 
Aspirin, some vitamins and most alkaloidal salts. 
9. Description: 
Magnesium stearate is a very fine, light white, precipitated or milled, 
Impalpable powdered of low bulk density, having faint odor of stearic acid and 
characteristic taste, The powder is greasy to the touch and readily adheres to the 
skin. 
10. Applications in Formulation or Technology: 
It is primarly used as lubricant in capsule and tablet manufacture at 
concentrations at between 0.25% and 5.0% w/w. It is also used in barrier creams. 
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4. AIM AND OBJECTIVE 
            The aim of this work is to develop a matrix tablet to completely deliver 
Zolmitriptan in controlled manner over a prolonged period which have low half life 
requiring frequent administration. 
 Zolmitriptan is an oral antimigrane agent, which is a commonly prescribed 
for the treatment of patients with migrane attacks. Zolmitriptan is a weak base(pKa 
= 9.6). soluble in water and 0.1N HCl acid environment and highly soluble less 
permeable (class III) drugs according to the Biopharmaceutical Classification 
System (BCS). 
 The oral absorption is uniform, slow with a bioavailability of nearly 40% and 
reported to have a short biological half-life (3±0.6 hrs) requiring it to be 
administered in 2 to 3 doses of 2.5 to 5mg per day. CR formulations that would 
maintain plasma levels of drug 8 to 12 hrs might be sufficient dosing for 
Zolmitriptan. SR products are needed for Zolmitriptan to prolong its duration of 
action and to improve patience compliance. 
The polymer selected for the present work was Hydroxypropyl 
methylcellulose (HPMC) K4M, K15M, K100M Grades, and combination with Ethyl 
cellulose (EC), and Cellulose Acetate phthalate (CAP). The effect of polymer types 
and drug:  polymer ratio on release also studied. Hydrophilic polymer matrix system 
are widely used for designing oral controlled release delivery systems because of 
their flexibility to provide a desirable drug release profile, cost effectiveness, and a 
broad regulatory acceptance. 
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In this formulation method combination of Ethyl cellulose and Cellulose 
acetate phthalate with different grades of HPMC K4M, K15M, K100M were used to 
control the drug release from the polymer. Formulation with these polymers will 
leads to slow release of drug from the polymer matrix either by diffusion or by 
dissolution method following drug kinetic release. 
Formulation of Zolmitriptan in the form of matrix tablets leads to prolonged 
action of drug where the drug binds  to the receptor site and drug released from the 
matrix slowly either in the diffusion or dissolution process and shows action on the 
target site for long time. 
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4. PLAN OF WORK 
STAGE-I: PREFORMULATION STUDY 
1. Pre Formulation Study of Pure Drug 
2. Compatibiity Study 
  Fourier transforms infrared spectroscopy (FT-IR) 
3. Preparation of standard curve of zolmitriptan 
STAGE-II: FORMULATION& EVALUATION 
Formulation and evaluation of controlled relaese matrix tablets 
1. Precompression parameter 
2. Formulation of zolmitriptan controlled release matrix tablets 
3. Evaluation of zolmitriptan controlled release matrix tablets 
 a) Physical evaluation  
 b) Drug content study  
 c) Dissolution study  
d) Kinetic study 
STAGE-III 
 Accelerated stability study of the optimized formulation. 
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5. MATERIALS AND METHODS 
List of material and equipments used was given in table No. 5 & 6 
Table 5: List of material used 
S.No Materials Manufacturer 
1 Zolmitriptan Reddys labs Ltd, Hyderabad 
2 HPMC K4M Colorcon Asia Pvt Ltd 
3 HPMC K15M Colorcon Asia Pvt Ltd 
4 HPMC K100M Colorcon Asia Pvt Ltd 
5 EC Signet chemicals 
6 CAP Signet chemicals 
7 Lactose Vilin Bio med Ltd,Roorkee,Ind 
8 Aerosol Stumester lab 
9 Talc S.D.Fine chemicals Pvt.Ltd 
10 Magnesium Stearate HimediaPvtLtd,Mumbai 
 
Table 6: List of equipments used 
S.No Equipments Company 
1 Sixteen station rotary tablet punching 
machine 
Cadmach, Ahmadebad, India 
2 Electronic digital balance Shimadzu corp., Japan 
3 Double beam UV-spectrophotometer Elicopvt India Ltd, Hyderabad. 
4 Dissolution tester ( USP ) Lab India  
5 Rotary shaker RemiEquipments Ltd 
6 Roche friabilator INCO Instruments and chemicals 
Pvt Ltd; Ambalacity,India 
7 Digital verniercallipers Mitutoyo Corp, Kawasaki,japan 
Chapter 5 Materials and Methods 
 
Dept. of Pharmaceutics 55 JKK Nattraja College of Pharmacy 
METHODS 
5.1. PREFORMULATION STUDIES: 
Preformulation may be described as a phase of the research and development 
process where the formulation scientist characterizes the physical, chemical and 
mechanical properties of new drug substances in order to develop stable, safe and 
effective dosage forms. 
The following preformulation studies were Performed: 
 Study of organoleptic properties 
 Solubility analysis 
 Melting point of drug 
 Drug powder characterization 
 drug-excipients compatibility study by FT-IR 
5.1.1 Organoleptic properties: 
Colour :a small quantity of pure Zolmitriptan powder was taken in a butter 
paper and viewed in well illuminated place. 
Taste and odour : very less quantity of Zolmitriptan was used to get taste 
with the help of tongue as well as smelled to get the odour. 
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 5.1.2. Solubility analysis: 
Solubilityis an important pre-formulation parameter because it affects 
thedissolution and bioavailability of drug. 
Method: Solubility of Zolmitriptan was determined in methanol, 
water,dicholoro methane, toluene and0.1N HCl.Solubility studies were performed 
by taking excess amount of Zolmitriptan in different beakers containing the solvent. 
The mixture was shaken for 10 hrs at regular intervals. The solution was filtered by 
using whatmann filter paper.  
5.1.3. Melting Point 
The melting point of Zolmitriptan was determined by capillary method, 
using small quantity of Zolmitriptan was taken and placed in apparatus and 
determined the melting point and matched with standards. 
5.1.4. Loss on drying 
Determined on 1 g by drying in an oven at 100°C to 105°C for 3 hours. 
Mixed and accurately weighed the substance to be tested. Tare a glass stopper, 
shallow weighing bottle that has been dried for 30 minutes under the same 
conditions to be employed in the determination. Weighed the empty bottle (W1). Put 
the sample in bottle, replaced the cover, and accurately weighed the bottle with 
contents (W2). By gently, sidewise shaking, distributed the sample as evenly as 
practicable to a depth of about 5 mm. Placed the loaded bottle in the drying 
chamber. Dried the sample at the specified temperature in a desicator before 
weighing. Weighed the bottle (W3).The difference between successive weights 
should not less than 0.3%. 
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The loss on drying is calculated by the formula: 
%LOD=
()
()
 x100 
Where, W1 = Weight of empty weighing bottle 
W2 = Weight of weighing bottle + sample 
W3 = Weight of weighing bottle + dried sample 
5.1.5. Drug Powder characterisation 
5.1.5.1. Angle of repose: Angle of repose is the maximum angle of a stable slope 
determined by friction, cohesion and the shapes of the particles. The internal angle 
between the surface of the pile and horizontal surface is known as the angle ofrepose 
and is related to the density, surface area and co-efficient of friction of the raw 
material. 
Method: Angle of repose was determined by using funnel method. The 
height of the funnel was adjusted in such a way that the tip of the funnel just touches 
the heap of the blends. Accurately weighed blend is allowed to pass through the 
funnel freely on the surface. The height and diameter of the powder cone was 
measured and angle of repose was calculated using the following equation. 
θ =  tan (h/r) 
Where, h = height of heap, r = radius of heap, θ = angle of repose. 
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Table7: Limits 
Angle of repose Flow property 
<25° Excellent 
25-30° Good 
30-40° Passable 
>40° Very poor 
 
5.1.5.2. Bulk density: Bulk density is defined as the mass of the powder divided by 
the bulk volume. Bulk density largely depends on particle shape, as the particle 
become more spherical in shape, bulk density was increased. In addition as the 
granule size increases bulk density decreases. 
Method: A quantity of 4gm of powder weighed and transferred to a measuring 
cylinder. The bulk volume and weight of the powder was determined.Bulk density 
was calculated using the formula. 
Bulk Density = Bulk Mass / Bulk Volume 
5.1.5.3. Tapped density: It is the ratio of total mass of the powder to the tapped 
volume of powder. The volume was measured by tapping the powder.Then the 
tapping was done and the tapped volume was noted. The tapped density was 
calculated using the following formulae 
Tapped Density =   

 
Where, m = initial weight of material in gm, Vf= volume of material 
aftertapping.Generally replicate determinations are desirable for the determination 
of thisProperty. 
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5.1.5.4. Measurement of Powder Compressibility: 
Based on the apparent bulk and the tapped density, the percentage 
compressibility of bulk was determined by the following formula. 
Compressibility index: = 100 
( )

 
Where, Vf= final tapped volume, Vo = initial un tapped volume 
Table-8: Limits 
S.No Compressibility index Flow 
1  5-12  Free flow  
2  12-16  Good flow  
3  18-21  Fair  
4  23-25  Poor  
5  33-38  Very poor  
6  >40  Extremely poor  
 
Hausner’s Ratio: =°

 
Where, Vf = final tapped volume, Vo = initial un tapped volume. 
Table-9: Limits 
S.No Hausner’s ratio Flow 
1 1-1.2 Free flowing 
2 1.2-1.6 Cohesive powder 
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5.2. COMPATIBILITY STUDY: 
   ! "# $%!&# ' ( #) *#+ * : 
IR spectra of drug, polymer and drug and polymers, individual excipients,drug 
and polymers and excipients were obtained using bruker. 
Method: Drug and excipients were analyzed by IR spectral studies by using 
KBr pellet technique. In this method, the drug and KBr were mixed at the ratio of 
1:100. Then these mixtures were pressed in to a pellet. The FT-IR spectra were 
recorded using bruker alpha in the region 400-4000 ,-. Spectra were recorded for 
pure drug,excipients, and physical mixture of drug and polymer, drug, polymer and 
excipients. 
5.3. STANDARD CURVE OF ZOLMITRIPTAN 
Calibration curve of Zolmitripitan was plotted in 0.1N HCl buffer and was 
estimated spectrophotometrically at λ max of 283nm. 
5.3.1. Preparation of 0.1N Hcl solution: 
Weighed 8.5 ml concentrated HCl was dissolved in 1000ml of distilled water 
to prepare 0.1N HCl solution. 
5.3.2. PREPARATION OF STANDARD SOLUTION 
1. Stock solution 
First stock solution of Zolmitriptan was prepared by dissolving 100mg in 
100ml of 0.1 N HCl. So as to get solution of 1mg/ml concentration. 
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2. Standard solution 
10 ml of 1mg/ml stock solution was diluted to 100ml with 0.1 N HCl buffer 
thus giving a concentration of 100 µg/ml from the above 10ml of prepared solution 
diluted to 100ml with buffer thus giving a concentration of 10 µg/ml. Accurately 
measured aliquot portion of standard drug solution ( 10 µg/ml) 0.5ml, 1.0ml, 1.5ml, 
2.0ml, 2.5ml, 3.0ml, 3.5ml, 4.0ml, 4.5ml, 5.0ml were transferred in to a 10 ml 
volumetric flask and was diluted up to the mark with the buffer thus the final 
concentration ranges from 5-50 µg/ml. Absorbance of each solution was measured at 
283nm against buffer. A graph of concentration of drug vs absorbance was plotted. 
5.4. FORMULATION DEVELOPMENT 
 Zolmitriptan matrix tablets were prepared by mixing manually in poly bags 
with different viscosity grades of HPMC such as HPMC K4M, HPMC K15M, HPMC 
K100M and in combination with EC and CAP. Tablets were prepared by direct 
compression method to observe the in vitro dissolution of drug from HPMC polymers 
at different concentration such as 10%,20%,30% to the target weight (100 mg) which 
was kept constant in all formulation F1 to F15. Accurately weighed quantity of 
drug,polymer and lactose were directly mixed uniformly and then the mixed blend 
was pre-lubricated with talc and Aerosil and finally lubricated with magnesium 
stearate manually in polybags for 5-10 min. The concentration of the HPMC K4M, 
HPMC K15,HPMC K100 in different formulation are (10%), (20%),(30%). The 
lubricated blend was evaluated for precompression parameter to determine the flow 
property of the powder and compressed into tablet by using 6.0mm punch. The 
formulation composition of F1 to F15 was given in table No.10. 
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Table 10 Formulation composition of zolmitriptan tablet  (qty. in mg) 
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 
1 Zolmitriptan 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
2 HPMC K4M 10 20 30 - - - - - - - - 30 - - 30 
3 HPMC K15M - - - 10 20 30 - - - - 20 - - 20 - 
4 HPMC K100M - - - - - - 10 20 30 10 - - 10 - - 
5 Cellulose acetate 
Pthalate 
- - - - - - - - - - - - 5 5 5 
6 Ethyl cellulose - - - - - - - - - 5 5 5 - - - 
7 Lactose 79.25 69.25 59.25 79.25 69.25 59.25 79.25 69.25 59.25 79.25 69.25 54.75 79.25 69.25 59.25 
8 Aerosil 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
9 Talc 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 Magnesium 
stearate  
0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 
11 Total weight 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
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5.4.1. Pre compression parameter  
 The lubricated blend of all formulation was examined for pre-compression 
parameter like angle of repose, bulk, density, tapped density, carr’sndex, hausner’s 
ratio, as given in preformulation section.  
5.5 EVALUATION OF CONTROLLED RELEASE MATRIX TABLET OF 
ZOLMITRIPTAN  
5.5.1. PHYSICAL EVALUATION 
5.5.1.1. Tablet Thickness 
 Ten randomly selected matrix tablets from each abtch were used for 
thickness determination. Thickness of each tablets was measured by using Digital 
vernier caliper. Mean and standard deviation were computed and reported 
5.5.1.2. Weight variation  
 The USP weight variation test was carried out by weighing 20 tablets 
individually, calculating the average weight, comparing the individual tablet weight 
to average weight.   
% Deviation  = (Individual weight – Average weight / Average weight)×100 
Table11: Pharmacopoecial Specifications for tablet weight variation 
Average weight of 
tablet (mg) (I.P) 
Average weight of tablets 
(mg) (U.S.P) 
Maximum Percentage 
difference allowed 
1 Less than 130 10 
2 130-324 7.5 
3 More than 324 5 
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5.5.1.3. Hardness 
 Hardness of tablet was determined using the Monsanto hardness tester.  The 
lower plunger was placed in contact with the tablet and a zero reading was taken.  
The plunger was then forced against a spring by tuning a threaded bolt until the 
tablet fractured.  As the spring was compressed a pointer rides aslongaguage in the 
barrel to indicate the force.  Mean and standard deviations were computed and 
reported.  It is expressed in kg/cm2.  
5.5.1.4. Friability  
 The Roche friability test apparatus was used to determine the friability of the 
tablets.  Twenty pre-weighed tablets were placed in the apparatus, which was given 
100 revolutions.  After which the tablets were reweighed.  The percentage friability 
was calculated.  
                                       Initial weight - Final weight X 100 
Percentage friability  = ------------------------------------------- 
                                                        Initial weight 
5.1.1.5. Drug Content 
 Five tablets of each formulation were weighed and powdered.  The quantity 
of powder was equivalent to 10 mg.  The equivalent weight zolmitriptan was 
transferred in to 100 ml volumetric flask and dissolved by using pH 6.8 as the 
extracting solvent and samples were analysedspectrophotometrically 227nm.   
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5.5.2. SWELLING INDEX STUDY 
Swelling behavior of different viscosity grades of HPMC, Ethyl Cellulose, 
Cellulose Acetate Pthaltein the 0.1 N Hcl dissolution medium. 
The mechanism of drug release from hydrophilic polymeric matrice involves 
solvent penetration, hydration and swelling of the polymer, diffusion of the 
dissolved drug in the matrix. Initially, the diffusion coefficient of drug in the 
dehydrated polymer matrix is low it increases significally as the polymer matrix 
imbibes more and more water and forms a gel as time progresses. The hydration rate 
of the polymer matrix, and there by the gel formation depends significantly on 
polymer proportion, viscosity and to a lesser degree on polymer particle size. So 
swelling study was performed according to the method reported by AL-Taani and 
Tashtoush to understand the influence of swelling behaviour on drug release and to 
determine the effect of polymer viscosity on swelling. For determination of swelling 
index one tablet from each formulation was kept in the petri dish containing 0.1 N 
HCl. After every2 hrs tablet was with drawn, soaked with tissue paper and weighed. 
The process is continued for 12hrs. 
Swelling index of formulation was calculated using following formula. 
.. 0 =
1# − 1$
1$
× 455 
Where, SI = Swelling index, Mt = Weight of tablet at time ‘t’ And Mo = 
weight of tablet at time ‘f ’. 
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5.5.3. IN-VITRO DISSOLUTION STUDY 
Table 12: In-vitro dissolution study 52, 53 
Apparatus Dissolution test apparatus (USP XXIII) 
Method USP type 2 apparatus (paddle method) 
Dissolution medium 0.1N HCl 
Volume  500ml 
Temperature  37 ± 0.5 0 C 
Speed 50 rpm 
 
Procedure: 
The tablet was placed inside the dissolution vessel. 5ml sample were 
withdrawn at time intervals of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12 hrs.The volume of 
dissolution fluid adjusted to 500 ml replacing fresh 5 ml of dissolution medium after 
each sample withdrawing. The release studies were conducted with 3 tablets and the 
mean value were plotted vs time. Each sample were analyzed at 283nm. The drug 
concentration was calculated using standard calibration curve. 
According to USP-29 specification 
At 1st hour - between 10-25% 
At 9th hour - between 45-85% 
At 12th hour - no less than 70% 
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5.5.4. Kinetic study 
Various kinetic models were used to describe the release kinetics. The zero 
order rate Eq. (1) describes the systems where the drug release rate is independent of 
its concentration. The first order Eq. (2) describes the release from system where 
release rate is concentration dependent. Higuchi described the release of drugs from 
insoluble matrix as a square root of time dependent process based on fickian 
diffusion Eq. (3). TheHixson-Crowell cube root law Eq. (4) describes the release 
from systems where there is a change in surface area and diameter of particles or 
tablets.     
C = kot (1) 
Where, Ko is zero-order rate constant expressed in units 
ofconcentration/time and t is the time. 
LogC= LogCo- kt/ 2.303 (2) 
Where, Co is the initial concentration of drug and K is firstorder constant. 
Q = kt½   (3) 
Where, K is the constant reflecting the design variables of the system. 
Q 0 1/3 – Qt 1/3 = kHC t (4) 
Where, Qt is the amount of drug released in time t, Q0 is the initial amount of 
the drug in tablet and KHC is the rate constant for Hixson-Crowell rate equation. 
The following plots were made: cumulative % drug releasevs. time(zero order 
kinetic model); log cumulative of %drugremaining vs. time (first order kinetic 
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model); cumulative %drug release vs. square root of time (higuchi model) and cube 
root of drug % remaining in matrix vs. time (hixsoncrowell cube root law).  
Mechanism of Drug Release 
Korsmeyer et al derived a simple relationship whichdescribed drug release 
from a polymeric system (Equation 5).Tofind out the mechanism of drug release, 
first 60% drugrelease data was fitted in Korsmeyer–Peppas model by plotting log 
cumulative % drug releaseVs log time: 
Mt / Mα = kKPtn(6) 
Where Mt / Mαis fraction of drug released at time t, kKP is the rate constant 
and n is the release exponent. The n value is used to characterize different release 
mechanisms as given in table for cylindrical shaped matrices. The value of n≤0.45 
indicates a classical fickian diffusion-controlled (case I) drug release, n = 0.89 
indicates a case II relaxational release transport; non-fickian, zero-order release and 
n>0.89 indicates super case II (increased plasticization at the relaxing boundary) 
type of release. Values of n between 0.45 and 0.89 can be regarded as an indicator of 
both phenomena (drug diffusion in the hydrated matrix and the polymer relaxation) 
commonly called anomalous transport. 
5.6. STABILITY STUDY 
 The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of variety of 
environemntl factors such as temperature, humidity and light.  And to establish a 
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retest for the drug substance or a shelf life for the drug product and recommended 
storage conditions.  
 The storage conditions used for stability studies were accelerated condition 
(40oC+2oC/75%RH).  Stability study was carried out for the optimized formulation.  
Tablets of optimized formulation were striped packed and kept in humidity chamber 
for 90 days on above mention temperature.  
The following tests are performed at an interval of 30 days for 90 days.  
Test performed 
• Drug content 
• Dissolution profile 
• Test for other physical parameters (hardness, weight variation, friability)  
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6. RESULTS AND DISCUSSION 
6.1. PREFORMULATION STUDY 
6.1.1. Observation of organoleptic properties 
Table No: 13 
Test Specification Observation 
Colour White to off-white crystalline powder 
Odour        - Odourless 
 
6.1.2. Solubility analysis 
Zolmitriptan sample are examined and it was found to be readily soluble in  
methanol, sparingly soluble in dichloromethane,practically insoluble in toluene. 
6.1.3. Melting point of Drug 
 The melting point of zolmitriptan was determined by capillary method, 
melting point of zolmitriptan was found to be 139º C melting point compared with 
USP standards that showed that drug is pure.  
6.1.4. Loss on drying 
 It was determined as per procedure given in methodology.  The results are as 
follows. 
Table No : 14 Observations for loss on drying 
Test Loss on drying Observation 
Loss on drying Not more than 0.5% 0.31% 
 
The loss on drying of drug was founded as 0.31 which is with in the limit. 
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6.1.5. Drug Powder characterization 
6.1.5.1. Angle of repose  
 It was determined as per procedure given in material and methodology 
section 5.1.5.1. 
Table No: 15 
Material Angle of repose 
Zolmitriptan raw material 27º56" 
 
The result indicating that the raw material has very good flow property. 
6.1.5.2. Flow properties 
 Flow property of pure drug determined according to the procedure given in 
methodology 5.1.5.2, 5.1.5.3, 5.1.5.4, section the results were given in table No. 16 
Table No:16 Flow propertie of pure drug 
Material Bulk density 
Tapped 
density 
Carr’s index 
(%) 
Hausner ratio 
(%) 
Zolmitriptan 
raw material 
0.34gm/ml 0.546gm/ml 15.05 1.57 
 
The results are clearly indicating that the zolmitriptanhas good flow 
property. 
  
Chapter 6 Results and Discussion 
 
Dept. of Pharmaceutics 72 JKK Nattraja College of Pharmacy 
6.2. Drug – Excipient compatibility test  
FTIR study on drug, drug with different polymer such as HPMC K4, HPMC 
K100M, EC, CAP were performed. The FTIR peak value spectrum were given in 
Table No : 17 to 20 and Fig No. 3 to 12 
 
Fig. 3 FTIR study of Zolmitriptan 
 
Fig. 4 FTIR study of  Zolmitriptan with HPMCK4 Polymer 
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Fig. 5FTIR study of  Zolmitriptan with HPMCK4 + EC 
 
 
Fig. 6FTIR study of  Zolmitriptan with HPMCK4 + CAP 
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Fig. 7FTIR study of  Zolmitriptan with HPMCK15 
 
 
 
 
Fig. 8 FTIR study of  Zolmitriptan with HPMCK15 + EC 
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Fig. 9 FTIR study of  Zolmitriptan with HPMCK15 + CAP 
 
 
 
Fig.10FTIR study of Zolmitriptan  with  HPMCK 100   polymer 
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Fig.11FTIR study of  Zolmitripitan with EC+HPMCK100(10%) 
 
 
Fig.12FTIR study of  Zolmitripitan with CAP+HPMCK100(10%) 
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Table No : 17 FTIR peaks of various components of zolmitriptan 
S.No 
Peak in pure drug 
(cm-1) Functional group Type of vibration 
1 3348.75 Amine (-N-H) Stretch (medium) 
2 2948.75 Aromatic (-C-H) Stretch(medium) 
3 1731.54 Amide (C=O) Stretch(strong) 
4 1407.68 Methylene  
cyclo hexane 
Stretch(scissoring) 
5 1047.68 Sulfoxide Stretch(strong) 
6 1020.63 Aromatic plane 
bending (C-H) 
Stretch(medium) 
7 1009.64 Aromatic (C=C) Stretch 
(weak multiple) 
 
 The FTIR spectral analysis showed that there is change in percent 
transmittance which may be due to change in crystalline and there is no appearance 
of disappearance of any characteritstic peaks of pure drug Zolmitriptan and in the 
physical mixture of drug and polymer, which confirms the absence of chemical 
interaction between drug and polymers.  
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Table No : 18 FTIR spectrum zolmitriptan with HPMC K4 Ec and CAP 
pepared Formulation 
Zolmitriptan Drug+HPMC K4M Drug+HPMC K4 (10%)+EC 
Drug+HPMC 
K4 (10%)+CAP 
526.69 529.60 532.60 545.69 
567.67 604 1010.49 660.72 
649.61 632.53 1019.42 878.81 
967.60 1019.39 1041.45 900.81 
1008.68 1038.40 1081.49 1019.65 
1031.68 1071.47 1368.74 1034.65 
1044.71 1258.74 1350.80 1347.85 
1258.62 1347.76 1352.84 1387.75 
1407.62 1359.60 1477.81 1389.87 
1731.54 1429.78 1756.88 1389.87 
2085.93 1739.89 2979.85 1425.87 
2877.82 2915.82 2900.80 1733.93 
2917.84 3337.75 3376.75 2900.87 
2860.62 3629.88 - 2937.90 
2925.82 - - 3337.65 
2933.68 - - - 
3556.72 - - - 
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Table No : 19 FTIR spectrum peak of Zolmitriptan with HPMC K15,EC,CAP. 
Zolmitriptan Drug+HPMC K15M 
Drug+HPMC K15 
(10%)+EC 
Drug+HPMC 
K15 (10%)+CAP 
556.69 568.75 587.79 590.65 
54867 603.51 1005.49 602.72 
649.61 637.74 1017.47 877.47 
956.68 1017.49 1037.42 910.81 
1008.69 1047.61 1071.49 1026.68 
1026.68 1058.61 1349.76 1037.68 
1047.71 1268.74 1368.80 1374.69 
1259.65 1351.76 1389.65 1369.87 
1407.68 1359.76 1422.87 1386.95 
1756.54 1422.78 1746.88 1389.65 
2087.65 1756.87 2936.65 1427.87 
2778.65 2900.80 2900.84 1737.93 
2819.84 3337.74 3326.84 2954.84 
2860.65 3526.89 - 2937.65 
2926.65 - - 3327.65 
2948.75 - - 3624.43 
3346.85 - - - 
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Table No:20 FTIR spectrum peak point of Zolmitriptan with HPMC 
K100,EC,CAP. 
Zolmitriptan Drug+HPMC K 100M 
Drug+HPMC K 
100(10%)+EC 
Drug+HPMC 
K100(10%)+CAP 
524.69 552.45 552.49 552.69 
548.67 603.51 1005.49 602.72 
648.61 632.53 1019.42 877.81 
947.68 1019.39 1031.42 900.81 
1009.68 1031.40 1071.49 1019.65 
1020.68 1071.47 1341.78 1031.65 
1042.71 1260.78 1360.80 1341.85 
1258.62 1341.76 1382.82 1360.87 
1407.68 1359.79 1422.81 1382.87 
1731.54 1422.78 1736.88 1382.87 
2082.93 1736.86 2932.85 1421.87 
2777.82 2900.80 2900.81 1735.93 
2819.84 3338.73 3328.76 2900.87 
2860.84 3524.89 - 2932.90 
2925.84 - - 3323.83 
2948.75 - - 3624.93 
3348.75 - -- - 
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6.3  Standard calibration curve for Zolmitriptan 
Initially the pure zolmitriptan was scanned in between UV-range such as 
200-400nm.The maximum absorbance for zolmitriptan was found at 283 nm. A 
standard concentration of zolmitriptan in the range of 5-50 µg/ml was prepared in 
0.1 N HCl buffer and the absorbance was measured at 283nm. Zolmitriptan is 
showing good linearity between 5-50 µg/ml with a correlation coefficient of 0.999. 
Table : 21 Standard value of zolmitriptan 
Concentration(µg/ml) Absorbance(nm) 
0 0 
5 0.097 
10 0.178 
15 0.266 
20 0.355 
25 0.442 
30 0.539 
35 0.617 
40 0.728 
45 0.807 
50 0.907 
 
 
Figure:13 Standard curve of zolmitripitan in 0.1 N HCl 
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6.4 Pre compression Parameter  
 The lubricated blend of all formulation examined according to standard 
procedure given in methodology and results were given in table No. 22 
Table : 22 Pre compression Parameter 
Formulation 
Code 
Angleof 
repose 
(degree± 
SD) 
BD 
(gm/ml± 
SD) 
TD 
(gm/ml± 
SD) 
Carr’s 
index 
(%± SD) 
Hausner 
ratio 
(%± SD) 
F1 26.81±0.02 0.42±0.02 0.52±0.02 16.71±0.02 1.16±0.05 
F2 27.71±0.09 0.43±0.09 0.53±0.09 17.28±0.09 1.18±0.04 
F3 28.54±0.06 0.45±0.06 0.54±0.06 15.44±0.06 1.16±0.02 
F4 29.73±0.08 0.43±0.08 0.56±0.08 13.44±0.08 1.19±0.04 
F5 27.54±0.07 0.45±0.07 0.58±0.07 15.69±0.07 1.14±0.06 
F6 25.61±0.09 0.46±0.09 0.59±0.09 17.76±0.09 1.13±0.06 
F7 28.61±0.06 0.53±0.06 0.53±0.06 14.46±0.06 1.19±0.03 
F8 27.73±0.08 0.49±0.08 0.52±0.08 14.44±0.08 1.15±0.01 
F9 26.33±0.02 0.52±0.02 0.51±0.02 15.44±0.02 1.18±0.03 
F10 27.38±0.09 0.41±0.09 0.54±0.09 14.64±0.09 1.17±0.05 
F11 26.66±0.08 0.47±0.08 0.53±0.08 16.28±0.08 1.16±0.04 
F12 28.52±0.06 0.45±0.03 0.58±0.03 15.18±0.03 1.17±0.02 
F13 27.53±0.04 0.42±0.02 0.57±0.02 14.28±0.02 1.15±0.01 
F14 26.52±0.08 0.49±0.01 0.52±0.01 15.72±0.01 1.19±0.04 
F15 29.75±0.09 0.43±0.04 0.53±0.04 16.18±0.04 1.18±0.06 
 
 The angle of repose values were ranged from 25º61"±0.06 to 29º75"±0.09. 
The results were found to be below 30; hence they have good flow ability. The 
Carr’s Index value ranged from 13.44±0.08 to 17.76±0.09 and Hausner ratio value 
ranged from 1.13±0.06 to 1.19±0.04,For all formulations hence they have good flow 
and free flow ability.  It was suitable for direct compression technique.  So 
according to F1 to F15 the tablets were formulated by direct compression technique.  
as per the procedure given in 5.4. 
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6.5 EVALUATION OF CONTROLLED  RELEASE MATRIX  TABLETS  OF  ZOLMITRIPTAN   
6.5.1 Physical evaluation various physiochemical properties were studied and summarised in table no:23 
Table :  23 Physical parameters of the prepared Zolmitriptan matrix tablet 
F. Code  Weight variation (mg) Thickness (mm) Tablet hardness(kg/cm2) Friability(%) Drug content(%) 
F1 98.9±0.33 2.42±0.66 6.2±0.44 0.40 98.12±1.2 
F2 97.5±1.31 2.52±0.08 6.3±0.46 0.54 98.2±0.2 
F3 99.2±1.42 2.63±0.09 6.9±0.54 0.65 98.48±0.62 
F4 100.2 ±1.33 2.54±0.09 6.9±0.05 0.36 98.5±0.96 
F5 99.5 ±1.37 2.48±0.09 6.2±0.43 0.40 97.25±0.86 
F6 98.9±1.39 2.60±6.08 7±0.16 0.36 99.1±0.05 
F7 101.2±1.45 2.50±0.08 6 ±0.51 0.38 98.2±0.097 
F8 102±1.32 2.57±0.06 7.3±0.45 0.36 99.56±0.097 
F9 99.5±1.35 2.64±0.09 6.6±0.52 0.38 98.56±0.91 
F10 98.2±1.42 2.58±0.094 6.7±0.54 0.41 101±0.082 
F11 99.5±1.35 2.42±0.081 6.6±0.51 0.31 100.1 ±0.091 
F12 98.2±1.42 2.58±0.091 6.7±0.54 0.41 101±0.082 
F13 99.8±1.35 2.42±0.081 6.6±0.51 0.31 100.1±0.091 
F14 101±1.5 2.40±1.38 6.9±0.51 0.33 101.2±1.2 
F15 101±1.5 2.40±1.38 6.9±0.51 0.36 99.9±0.91 
Chapter 6 Results and Discussion 
 
Dept. of Pharmaceutics 84 JKK Nattraja College of Pharmacy 
Acceptable physiochemical properties were observed for the prepared matrix 
tablets. F1 to F3 which is containing HPMC K4 (10%, 20%, 30%). Friability of the 
prepared matrix tablets F1, F2, F3 was (0.40, 0.54, 0.65%) respectively, Indicating 
that friability is with in the acceptable limits. Hardness of the tablets was found to be 
good depending up on compression force applied (4-6.9 kg/cm2). The thickness of 
the tablets were found to be in the range of (2.42mm-2.63 mm).All the formulation 
shown uniform thickness which indicates good mechanical strength of the tablet. 
Drug content of the prepared matrix tablets was found to be in the range of 98.12-
98.48%. which is in the range as per the requirement of pharmacopoeia.  
Acceptable physiochemical properties were observed for the prepared matrix 
tablets. F4 to F6 which contain HPMC K15 10%, 20%, 30% respectively.Friability 
of the prepared matrix tablets was (0.36%,0.40%,0.36%). Indicating that friability is 
with in the acceptable limits. Hardness of the tablets was found to be good 
depending up on compression force applied (6.9-7 kg/cm2). The thickness of the 
tablets were found to be in the range of (2.54mm-2.60mm).All the formulation 
shown uniform thickness which indicates good mechanical strength of the tablet. 
Drug content of the prepared matrix tablets was found to be in the range of 98.5-
99.8%. which is in the range as per the requirement of pharmacopoeia.  
Acceptable physiochemical properties were observed for the prepared matrix 
tablets. Friability of the prepared matrix tablets was (0.38%, 0.36%, 0.38 %),F7 to 
F9 which contain HP mc k100 10%,20%,30% respectively indicating that friability 
is with in the acceptable limits. Hardness of the tablets was found to be good 
depending up on compression force applied (6-6.6kg/cm2). The thickness of the 
tablets were found to be in the range of (2.50mm-2.64mm).All the formulation 
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shown uniform thickness which indicates good mechanical strength of the tablet. 
Drug content of the prepared matrix tablets was found to be in the range of 98.56-
101%. which is in the range as per the requirement of pharmacopoeia.  
Acceptable physiochemical properties were observed for the prepared matrix 
tablets F10 to F11 contained combination of Hpmck10010%,K1520%,K430% with 
ethyl cellulose. Friability of the prepared matrix tablets was (0.41%, 0.31%, 0.41%). 
Indicating that friability is with in the acceptable limits. Hardness of the tablets was 
found to be good depending up on compression force applied (6.6-6.7 kg/cm2). The 
thickness of the tablets were found to be in the range of (2.42mm-2.58mm).All the 
formulation shown uniform thickness which indicates good mechanical strength of 
the tablet. Drug content of the prepared matrix tablets was found to be in the range 
of  100-101%. which is in the range as per the requirement of pharmacopoeia.  
Acceptable physiochemical properties were observed for the prepared matrix 
tablets F12 to F15 which contained combination of Hpmc k10010%,K1520%,K430% 
with cellulose acetyl phalate Friability of the prepared matrix tablets was 
(0.31,0.33,0.36%). Indicating that friability is with in the acceptable limits. Hardness 
of the tablets was found to be good depending up on compression force applied (6.6-
6.9 kg/cm2). The thickness of the tablets were found to be in the range of (2.40mm-
2.42mm).All the formulation shown uniform thickness which indicates good 
mechanical strength of the tablet. Drug content of the preparedmatrix tablets was 
found to be in the range of 99.9.-100.1%.  
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6.5.2. SWELLING INDEX 
 Swelling index for all formulation F1 to F15 determined according to 
procedure given in 5.5.2.  The results were summarised in Table No.24 to             
Table No. 28 and Fig:14 to 18. 
Table: 24 Swelling index of Zolmitriptan matrix tablets prepared with  
HPMC K4M (10%,20%,30%) 
Time in hrs HPMC K4M 10% HPMC K4M 20% HPMC K4M 30% 
0 0 0 0 
2 114 140 164 
4 117 162 180 
6 121 178 210 
8 134 181 258 
10 111 200 259 
12 107 170 200 
 
 
Fig: 14  Swelling index vs.time of Zolmitriptan matrix tablets F1 to F3. 
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Table: 25 Swelling index of Zolmitriptan matrix tablets prepared with  
HPMC K15M (10%,20%,30%) 
 
 
Fig: 15 Swelling index of Zolmitriptan matrix tablets. 
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Time in hrs HPMC K15M 10% HPMC K15M 
20% 
HPMC K15M 30% 
0 0 0 0 
2 210 221 254 
4 230 243 256 
6 245 255 268 
8 250 267 271 
10 259 243 252 
12 200 198 220 
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Table: 26 Swelling index of Zolmitriptan matrix tablets prepared with  
HPMC K100M (10%,20%,30%) 
Time in 
hrs 
HPMC K100M 
10% 
HPMC K100M 20% HPMC K100M 30% 
0 0 0 0 
2 85 92 122 
4 105 115 137 
6 116 127 144 
8 122 131 151 
10 100 104 116 
12 93 99 108 
 
 
Fig: 16 Swelling index of Zolmitriptan matrix tablets F7 to F9. 
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Table: 27 Swelling index of Zolmitriptan matrix tablets prepared with Ethyl 
cellulose HPMCK4-K15-K100M(30%,20%,10%) 
Time in hrs EC+HPMC K4M 30% 
EC+HPMC K15M 
20% 
EC+HPMC 
K100M 10% 
0 0 0 0 
2 117 128 133 
4 124 139 148 
6 135 141 169 
8 148 157 178 
10 115 119 120 
12 108 112 118 
 
 
Fig: 17 Swelling index of Zolmitriptan matrix tablets F10 to F12. 
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Table: 28 Swelling index of Zolmitriptan matrix tablets prepared with 
Cellulose acetate phthalate HPMCK4-K15-K100M (30%, 20%, 10%) 
Time in hrs CAP+HPMC K4M 
30% 
CAP+HPMC 
K15M 20% 
CAP+HPMC 
K100M 10% 
0 0 0 0 
2 132 148 152 
4 145 159 168 
6 156 167 176 
8 162 188 200 
10 127 139 142 
12 120 125 136 
 
 
Fig: 18 Swelling index of Zolmitriptan matrix tablets F13 to F15. 
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The percentage water uptake of the formulations (F1-F15) was calculated 
Table 24 to 28. Results demonstrated enhancement in the swelling index with an 
increase in polymer concentration and also time duration. Increase in polymer 
concentration from 10 to 30% increased the swelling . From 2 to 12 hours in 
formulation. This may be due to the hydrophilic property of HPMC . Moreover, 
swelling of the polymer also leads to the formation of matrix, thereby retarding the 
release of drug from the formulation. 
Investigation of polymer swelling and erosion is a valuable exercise to better 
understand the mechanism of release and the relative importance of participating 
parameters. Matrix tablets of HPMC were found intact throughout the period of 
swelling (2 to12) in HCL and also the percent of swelling index was proportionate to 
the polymer level. On comparing the swelling indices of different matrix 
formulations, it was observed that, tablets containing combination of hydrophilic-
hydrophobic polymer blends swelled less than that of formulations containing 
hydrophilic polymer alone .This could be due to presence of non-swellable 
hydrophobic polymers, which minimized the swelling of the matrix tablets. 
6.3 IN VITRO  DISSOLUTION STUDY 
Invitro dissolution study was carried out by using USP dissolution 2 
apparatus.  The release profiles of formulations F1toF15, prepared by using HPMC 
K4 M, K15 M a K100 M,EC,CAP illustrated in (Table 29 ) and (Figure 19& 20 ). 
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Table: 29 INVITRO DRUG RELEASE STUDY OF FORMULATED CONTROLLED RELEASE TABLET 
Time 
(hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 40.3±1.20 36.6±2.42 32±1.36 35±1.20 32.7±1.36 30.6±2.38 29±1.2 26±1.6 20±0.43 25±0.76 26±0.87 30±0.45 25±0.99 26±0.56 30±0.84 
2 48±2.31 47.1±1.20 42.8±2.54 46±1.40 41±2.42 38±1.54 42±0.59 36±1.2 34.1±0.53 35±0.98 36±0.59 34±0.69 37±1.54 32±1.45 38±1.67 
3 59±0.25 58±0.20 53.6±1.56 57.3±2.20 53±2.12 46±1.14 50±0.45 41±1.65 41±0.69 44±1.18 45.7±1.44 37±1.55 46±1.79 40±1.86 40±1.43 
4 67±2.42 66.3±1.34 61±0.77 64±0.10 60.8±1.34 50.2±1.10 57±0.75 50±0.97 46±1.23 53±0.56 54±1.87 44±1.98 54±1.63 47±1.78 46.4±1.54 
5 76±1.40 73±1.10 68±1.40 72±2.25 68±1.20 59±0.20 62±1.54 58±0.58 50±1.48 62±0.85 63.3±1.90 50±0.97 63±1.34 54±1.98 53±1.98 
6 89±1.10 80±0.30 74±3.24 78±1.26 70±0.36 64±0.28 70±1.48 63±1.45 55±1.25 70±1.17 71±1.38 58±1.67 71±0.56 60±1.43 60±0.78 
7 98±2.35 89±2.62 81±2.25 84±1.30 79±0.28 70±1.15 75±0.93 71±1.22 59±1.48 75±1.87 76±1.06 64±1.89 76±0.29 65±1.38 66±0.78 
8  97±2.10 89±1.15 90±1.38 84±2.56 80±1.64 82±0.45 75±0.67 63±0.45 80±0.99 81±1.54 71±0.98 81±0,88 71±0.57 73±0.98 
9   98±0.47 98±0.10 91±1.24 87±2.25 90.2±1.32 83±2.10 70.4±1.82 83±1.57 86±1.39 82±0.43 86±1.43 80±0.65 86±1.26 
10     97.8±1.54 94±2.02 97.6±2.05 90±1.28 78±0.96 86±1.54 88±0.82 90±0.84 89±1.68 88±1.43 93±1.42 
11      98.8±1.00  98.7±0.62 85±0.76 89 92±0.47 99.1±1.98 91±1.78 94±1.20 99.4±1.38 
12         90.2±1.56 92.1 97±0.65  93±1.54 99.7±0.69  
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Figure: 19 Dissolution profile of prepared formulation F1-F7 
 
 
Figure: 20 Dissolution profile of prepared formulation F8-F15 
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temperature of 37±0.50c. Samples of 5ml were collected at different time intervals 
and analyzed spectrophotometrically at 283 nm.The effect of polymer level on release 
was studied by varying the levels of HPMC in the matrix tablets. The release pattern of 
matrix tablet containing 10,20 and 30% w/w HPMC, K4,K15,K15 with EC and CAP was 
decipated in Figure. The release rate from F1, F2 and F3 was found to be 98, 97 and 98% at 
the end of 7
th
, 18
th 
and 9
th
hrs respectively. profile of zolmitriptan Hcl from HPMC-K15 
matrix formulations F4, F5, and F6 were found to be 98, 97.8 and 98.8% at the end 
of 9 
th
, 10
th 
and 10
th 
hr respectively. The release profile of Zolmitriptan  from 
HPMC-K100 matrix formulations F7, F8, and F9 were found to be 97.6, 98.7 and 
90.2% at the end of 10th ,11th ,&12th hr respectively. The release rate decreased as 
the concentration of HPMC increased which showed that the presence of a highly 
water-soluble compound, Zolmitriptan, in a HPMC matrix generates an  additional 
osmotic gradient, thereby resulting  in a faster rate of polymer swelling and a  large 
increase in gel thickness. In the presence of a solvent, the mobility of the polymer 
chains is enhanced, resulting in a gradual transformation of a glassy matrix to a 
rubbery swollen gel. At higher polymer loading, the viscosity of the gel matrix is 
increased which results in a decrease in the effective diffusion coefficient of the 
drug. other  factors that may contribute to differences in drug dissolution profile as a 
function of  changes in total polymer concentration  include differences in water 
penetration rate,  water absorption capacity and polymer  swelling . 
As the proportion of HPMC was increased, there was a progressive decline in the 
release rate because of formation of thick gel structure that delayed the drug release from 
the matrices, where hydration of HPMC resulted in extensive swelling and increase in the 
diffusion path length. Swelling studies of HPMC matrices also showed proportionate 
increase in the swelling with increase in polymer level. However, the results of the in vitro 
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drug release studies indicated that, matrix tablets prepared using HPMC alone could not 
efficiently control the release of drug even with increased levels of polymers (up to 
30%w/w) and thus indicated the need for hydrophobic polymers in the HPMC matrices for 
controlling the drug  release over a period of 12 hrs. To assess the influence of hydrophobic 
polymers in controlling the drug release, six matrix formulations containing combination of 
HPMC-EC (F10-F12) and with equal proportions were prepared in different polymeric 
levels like 10, 20 and HPMC-CAP (F13-F15)30% w/w. Similarly, the matrices prepared 
using combinations of HPMC with EC were subjected for dissolution studies. The 
release pattern of matrix tablets containing HPMC-EC (F10-F12) is depicted in Fig. 
20. The release rate from matrix formulations F7, F8, and F9 was found to be 92.1, 
97 and 95% at the end of 12
th 
hrs respectively. The release profiles from HPMC-EC 
formulations showed due more hydrophobic nature of EC. In all the above 
formulations, delay in drug release was observed due to the presence of hydrophobic 
polymers like ethyl cellulose and CAP, which restricted the penetration of 
dissolution medium in side the matrix and also the formation of gel layer around the 
matrix. The observation is further supported by penetration theory, which states that, 
when a matrix is composed of a water-soluble drug and a water-insoluble polymer, 
drug release occurs by dissolution of the active ingredient through capillaries 
composed of interconnecting drug particle clusters and the pore network. As drug 
release continues, the interconnecting clusters increase the pore network through 
which interior drug clusters can diffuse with more hydrophobic particles present, 
and the theory predicts that fewer clusters of soluble drug substance are formed. 
Furthermore, the presence of finite drug clusters is more statistically plausible. The 
resulting pore network becomes less extensive and more tortuous resulting in slower 
drug release. The incorporation of CAP in the matrix not only helped to provide 
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good initial retardation in the release but also helps to enhance the overall release 
rate of the drug after a suitable lag time. The release profiles showed tri-phasic with 
initial burst effect (less than 30min) followed by a polymer-controlled slower release 
in the second phase. The difference in burst effect was the result of difference in the 
viscosity of the polymers. As it can be seen from (Figure 1) Polymeric system with 
low viscosity polymer (HPMC K4 M, K15 M) yielded a faster initial burst effect 
except HPMC K100 M. There has been considerable interest in using different 
grades of HPMC in controlled release drug delivery system due to their hydrophilic 
nature and fast hydration. In conclusion, the matrix tablets prepared with polymeric 
combination of HPMC-EC and HPMC-CAP showed better controlled release than 
those prepared using HPMC alone. Among all F1to15 formulation F14  shown  
better  release (99%in 12hrs )so F14 formulation which contain HPMC K15 +CAP 
was selected as optimised formulation . 
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6.5.4 KINETIC STUDIES OF ZOLMITRIPTAN CONTROLLED RELEASE 
MATRIX TABLETS: 
Table No: 30 
time  log 
time 
 
√time 
cumulative 
% drug 
release 
log 
cumulative 
% drug 
release 
cumulative 
% drug 
remained 
log 
cumulative 
% drug 
remained 
(hrs) 
1 0 1 26 1.4149 74 1.8692 
2 0.301 1.4142 32 1.5051 68 1.8325 
3 0.4771 1.732 40 1.602 60 1.7781 
4 0.602 2 47 1.672 53 1.7242 
5 0.6989 2.236 54 1.732 46 1.6627 
6 0.7781 2.4494 60 1.7781 40 1.602 
7 0.903 2.6457 65 1.8291 35 1.544 
8 0.903 2.828 71 1.8512 29 1.4623 
9 0.9542 3 80 1.903 20 1.301 
10 1 3.166 88 1.9444 12 1.0791 
11 1.0431 3.3166 94 1.9731 6 0.7781 
12 1.0791 3.4641 99.7 1.9956 1 0 
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Fig : 24 Zero Order Plot 
 
 
Fig : 25 First Order Plot 
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Fig : 26 Higuchi Plot 
 
 
Fig : 27KorsemeyerPeppas Plot 
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Table No. : 31 KINETICS OF DRUG RELEASE 
Formulation 
Zero Order 
Release R2 
First Order 
Release R2 
Higuchi 
Release 
R2 
Peppas 
R2 
Peppas 
n 
Order of 
Release 
F14 0.971 0.776 0.977 0.625 0.596 
Zero 
order 
Release 
 
In order to determine the mechanism of drug release from the formulation 
the in vitro dissolution data was fitted to zero order, first order ,higuchi and 
korsemeyar –peppas’s plot and interpretation or release exponent value (n) was 
calculated and results were shown in Table:31 and fig no:25 to 28.  
The model that best fits the release data was evaluated by correlation 
coefficient (r) [Table 31]. The correlation coefficient (r) values were used as the 
criteria to choose the best model to describe drug release from the  controlled release 
tablets. The r-values (r2= 0.977) obtained for fitting the drug release data to the 
Higuchi equation indicated that the drug release mechanism from these tablets was 
diffusion controlled. In most of the formulated tablets, the r2 values (0.971) were 
higher in zero-order models than in first-order (0.776) model, indicating that the 
drug release from the tablets was according to zero-order kinetics and thus showing 
that the drug release rate was independent of the residual concentration of drug. By 
using the release exponent value of was found to be 0.596 Korsmeyer-Peppas 
equation, the n values obtained were between 0.5221 and 0.8992 [Table 31] for  
formulation F14. These values are characteristic of anomalous kinetics (non-
Fickian)  
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STABILITY STUDIES 
 Zolmitriptan control matrix tablet were evaluated for accelerated stability 
studies at 40oC / 75% RH condition.  The stability details / results were presented as 
below. 
The product was evaluated for following para meters. 
1. Weight variation 
2. Hardness 
3. Friability 
4. Drug content 
5. Dissolution analysis 
Storage condition : 40oC / 75% RH 
Pack : HDPE (High Density Polyethylene) container 
Storage period : 1 month, 2 months, 3 months. 
Table No. 31 
TEST 0 Days 30 Days 60 Days 90 Days 
Weigth variation 99.8 ± 1.35 99.5 ± 1.35 98.9 ± 1.39 98.8 ± 1.42 
Hardness(kg/cm2) 7 6.9 6.9 6.6 
Friability 0.65 0.54 0.41 0.40 
Drug content 99.9 ± 0.91 99.1 ± 0.05 99.56 ± 0.097 99.1 ± 0.093 
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Table No. : 32 Cumulative dissolution profile of tablets after 1st month, 2nd 
month and 3rd month stability of F14 
Time in 
hours 0 days 
Cumulative % drug release 
1st month 2nd month 3rd month 
0 0 0 0 0 
1 26 26 26 25.8 
2 32 32 31.6 31.3 
3 40 40 39.8 39.5 
4 47 47 46.9 46.7 
5 54 54 53.7 53.5 
6 60 60 59.5 59.4 
7 65 65 64.7 64.6 
8 71 71 70.4 70.3 
9 80 80 79.6 79.5 
10 88 88 87.6 87.5 
11 94 94 93.4 93.3 
12 99.7 99.7 99.3 99 
 
Fig : 28 Dissolution data of Stability for sample F14 
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The stability studies for optimized formulation F14 was carried based 
accelerated stability conditions &Studty of various parameters carried out at 0, 30, 
60, 90 days of intervals and the results found satisfactoriliy and that reveals that the 
optimized formulation was stable under accelerated condition.  
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7. SUMMARY AND CONCLUSION 
Controlled release formulations in many case provide significant 
advantages,including improved theraupetic effect,increased patient compliance by 
reducing dosing frequency and decrease in incidence and or intensity of adverse 
effect by a constant blood concentration.The main objective of the present study was 
to develop controlled release matrix tablet formulation containing 5mg of 
zolmitriptan for the treatment of migraine. 
In the prefomulation, FTIR study was carried out for pure drug (zolmitriptan) 
zolmitriptan and excipients.  It has not shown any interaction.  Hence drugs were 
found to be compatible with excipients.  
  The angle of repose values for formulations range from 25.61±0.06 to 
29.75”±0.09 Bulk and tapped densities were used for the measurement of 
compressibility index.  The bulk and tapped values for formulations range from  
0.42± to 0.53±0.06   0.51±0.02±0.59±0.09 and to respectively the car’s index and 
hausner’s ratio values for formulations range from1.13±0.06 to 1.19±0.04 to 
respectively.  Thus all formulations exhibited good flow characteristics. The 
formulations F1 to F15 were prepared by direct compression method. 
The prepared controlled matrix tablets were evaluated for various parameters 
like thickness, weight variation, hardness, friability and drug content uniformity. 
The thickness of tablets in all formulations were ranged from 2.40±1.38 
to2.64±0.09. The weight variation of tablets in all formulations were ranged from 
100.2±1.33to102±1.32. The hardness and friability of all the formulations F1-F15 
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was found to be 6±0.51 to 7.3±0.45 and 0.31 to 0.65respectively.Drug content of all 
the formulations were ranging from 97.25±0.86 to 101.2±1.2.                     
Swellling index stugies were carried out indicating that according to the 
polymer concentration swelling index vary. 
The prepared tablets were then subjected to dissolution test for evaluating the 
invitro drug release .The dissolution studies were carried out in 0.1 N Hcl in USP II 
appatarus at 37±0.5°C. The results of the dissolution studies indicated that the 
polymer concentration was having a substantial effect on the drug release from the 
tablets .Formulation F14 which contained HPMC K15 (20%) and CAP have better 
controlled drug release (99.7% at 12 hrs) andincomparision to the other 
formulations. 
The kinetic study was carried out for F14 formulation which showed that the 
drug release followed zero order kinetics followed by non-fickian diffusion. 
The stability studies were carried out for F14 formulation at 40oC / 75% RH 
for 3months. Data revelead that there was no considerable difference. 
 From the above study, concluded that F14 was the optimized formulation, 
among all the  formulation F14 formulation containing CAP+HPMC K15M 20% 
shows that 99% drug release at the end of 12hrs emerging as best formulation which 
followed by zero order release kinetics non fickian diffusion release. 
In future,the following recommendations are made for continuation of 
experiment work  
1. In-vivo studies,   2.  Development of suitable packaging material. 
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